Methods for detecting analytes in media containing light-scattering components
By using flux and scattering signal detection of light-scattering components in nanopore sensing, the limitations of electrodetection and fluorescence detection are overcome, enabling rapid and sensitive analyte detection suitable for large-scale parallel systems.
Patent Information
- Application Number
- CN202180031357.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-04-03
- Filing Date
- 2021-04-01
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2041-04-01
AI Technical Summary
In existing nanopore sensing technologies, the electro-detection ion current method requires high salt concentrations and is difficult to address nanopores individually in large-scale parallel systems, while fluorescence signal detection relies on expensive indicator dyes and optical sensitivity limits the ability to quickly distinguish analytes.
By bringing the medium into contact with the nanopore, the flux of the light scattering component is used to generate a scattering signal through the nanopore. The medium near the nanopore is then illuminated with a light source, and the scattering signal is measured as the analyte moves relative to the nanopore. The scattering signal is detected using equipment such as a reflection interference microscope.
It enables rapid detection of analytes without the need for high salt concentrations and individually electrically addressed nanopores, avoids the effects of photobleaching, improves detection sensitivity and simplifies equipment, and is suitable for parallelization and miniaturization.
Smart Images

Figure CN115485552B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to methods for detecting analytes in optical detection media, as well as systems and apparatus for detecting analytes in optical detection media. The method is particularly suitable for detecting and characterizing analytes, such as polynucleotides and peptides. Background Technology
[0002] Nanopore sensing is a method for analyte detection and characterization that relies on the observation of individual binding or interaction events between analyte molecules and ion conduction channels. Nanopore sensors can be generated by placing nanoscale pores in an electrically insulating film and measuring signals, such as voltage-driven ion currents, that pass through or across the pores in the presence of analyte molecules. Typically, the presence of the analyte alters the measured signal, and the characteristics of the signal are characteristic of the analyte.
[0003] Peptides and polynucleotides are important analytes for sensing in this manner. Nanopore sensing of peptide and polynucleotide analytes can reveal the identity of the sensed analyte and perform single-molecule counting, but it can also provide information about its composition, such as its sequence, and the presence of features such as amino acid / base modifications, oxidation, reduction, decarboxylation, and deamination. Nanopore sensing has the potential to allow for rapid and inexpensive sequencing of polynucleotides and peptides, for example, providing single-molecule sequence reads of polynucleotides ranging from tens of thousands to hundreds of thousands (or even more) bases in length.
[0004] In some known nanopore sensing systems, the measured signal can be a voltage-driven ion current measured through the pore, and the current signal can be measured as the analyte interacts with the pore in the presence of an analyte such as a peptide or polynucleotide. For example, when the analyte is a polynucleotide, information about the properties of the polynucleotide can be determined based on the duration and extent of current blocking and the change in current level during the interaction between the polynucleotide and the pore. However, electrically detecting ion currents can be challenging, for example in massively parallel systems, such as extended nanopore arrays, because each nanopore in the array needs to be individually electrically addressable. Furthermore, generating ion currents of sufficient magnitude to allow proper differentiation of analytes often requires high salt concentrations that interact with or interfere with the analyte. Additionally, if multiple nanopores are present in an electrically addressable region, the recorded electrical signal reports the average ion current recorded for all present nanopores.
[0005] One proposed approach to address this problem is to use optical detection of analyte molecules as they interact with the pores. For example, one known method involves the optical encoding of ion flux. Fluorescence signals can be recorded from indicator dyes. These signals are generated by the flow of a cofactor specific to the indicator through the pore. A suitable indicator dye is, for example, the fluorescent molecule Fluo-8, which, in its cofactor Ca... 2+It emits fluorescence in its presence. Under the influence of an applied voltage, the cofactor (Ca) 2+ The continuous flow of the analyte through the pore results in a stable background fluorescence signal near the pore. The presence of the analyte impedes the flow of the cofactor, thus disrupting the fluorescence signal recorded near the pore. In this way, the optical fluorescence signal represents the ion current recorded in conventional nanopore techniques. Such techniques are described in Huang et al., Nature Nanotechnology 10, 986–991 (2015).
[0006] Despite the promising nature of this approach, significant challenges remain. For instance, the generation of fluorescence signals requires labeling the analyte (e.g., using indicator dyes as described above). Indicator dyes are typically expensive and can disrupt the system under investigation (e.g., by reacting with the analyte in question or altering its properties). Furthermore, fluorescence detection with adequate accuracy for single-molecule differentiation of analytes requires complex equipment, such as filter assemblies, cameras, and high numerical aperture optics, all of which are difficult to miniaturize for practical application. Moreover, the physics of fluorescence limits the practical application of such methods. First, a single fluorescent molecule can only acquire a limited photon flux, and the sensitivity of current optical techniques limits the maximum possible acquisition rate (i.e., minimum sampling time) of a single fluorophore to around 100 μs. Therefore, distinguishing analyte events occurring on faster timescales (e.g., differentiating individual nucleotides in polynucleotides as they move through a nanopore at rates greater than 100 μs / nucleotide) may be impossible. Second, photobleaching severely limits the maximum duration a single fluorophore can be detected, thus limiting the maximum possible acquisition time.
[0007] Given these issues, there is an urgent need for novel methods for optical detection of analytes as they move relative to nanopores. The method presented in this paper aims to address some or all of these problems. Summary of the Invention
[0008] This disclosure relates to a method for detecting an analyte in a medium containing a light-scattering component. The method includes contacting the medium with a nanopore, thereby generating a flux of the light-scattering component through the nanopore. The analyte contacts the nanopore such that the analyte affects the flux of the component through the nanopore. The medium near the nanopore is irradiated with one or more light sources, thus generating a scattering signal when light is scattered from the component. By measuring the scattering signal as the analyte moves relative to the nanopore, it can be detected while moving relative to the nanopore.
[0009] Therefore, this paper provides a method for detecting an analyte in a medium containing light-scattering components, the method comprising:
[0010] - To bring the medium into contact with the nanopores;
[0011] - Generates the flux of the component through the nanopores;
[0012] - Contact the analyte with the nanopore, such that the analyte affects the flux of the component through the nanopore;
[0013] - Irradiate the medium near the nanopore with one or more light sources; and
[0014] - As the analyte moves relative to the nanopore, the light scattered by the components near the nanopore is measured once or multiple times, thereby detecting the analyte as it moves relative to the nanopore.
[0015] In some embodiments, measuring the light scattered by the component once or multiple times includes generating a scattering signal corresponding to the flux of the component through the nanopore. In some embodiments, measuring the light scattered by the component once or multiple times includes detecting interference between the scattering signal and a reference beam. In some embodiments, interference is detected using a reflection interferometric contrast microscope, a digital holographic interferometric microscope, an interferometric scattering microscope (iSCAT), or a coherent bright-field interferometric microscope (COBRI).
[0016] In some implementations, the reference beam is reflected from the interface.
[0017] In some implementations, the flux of the component is from a first volume of medium to a second volume of medium, and one or more measurements of the light scattered by the component are taken in the second volume of medium near the nanopore.
[0018] In some embodiments, one or more light sources each independently include a laser, a superluminescent diode, and / or an incoherent source, preferably an LED or a lamp. In some embodiments, the scattered signal, the reference beam, and / or the interference between them are detected using a detector selected from CCDs, CMOS cameras, and point detectors such as photodiodes.
[0019] In some embodiments, the light-scattering component has a refractive index different from that of the medium. In some embodiments, the refractive index of the light-scattering component is greater than that of the medium.
[0020] In some embodiments, the component comprises a hydrophilic, water-soluble molecule. In some embodiments, the component is uncharged. In some embodiments, the component comprises sugars or polyethylene glycol. In some embodiments, the component does not contain a fluorophore.
[0021] In some embodiments, the flux of a component through a nanopore is driven by a physical or chemical potential. In some embodiments, the flux of a component through a nanopore is driven by a chemical concentration gradient across the nanopore.
[0022] In some embodiments, the analyte is a biopolymer. In some embodiments, the analyte is a polynucleotide or polypeptide. In some embodiments, the analyte is unlabeled or not optically labeled such as with a fluorophore or chromophore.
[0023] In some embodiments, the movement of the analyte relative to the nanopore is driven by a physical or chemical potential. In some embodiments, the method includes contacting the analyte with a dynein, wherein the dynein controls the movement of the analyte relative to the nanopore. In some embodiments, the dynein is a helicase, polymerase, exonuclease, topoisomerase, folding enzyme, or a variant thereof.
[0024] In some implementations, the medium contains an aqueous or non-aqueous solvent.
[0025] In some embodiments, the nanopore is a transmembrane nanopore. In some embodiments, the nanopore is a protein nanopore, a solid nanopore, a nucleic acid nanopore, or a polymer nanopore. In some embodiments, the nanopore is a β-barrel protein nanopore. In some embodiments, the nanopore is located within a membrane. In some embodiments, the nanopore is located within a droplet interfacial bilayer. In some embodiments, the nanopore is located in an array of multiple nanopores.
[0026] A method for characterizing an analyte is also provided, comprising performing the method described herein; and performing one or more measurements as the analyte moves relative to the nanopore, wherein the one or more measurements indicate one or more properties of the analyte, and thereby characterizing the analyte as it moves relative to the nanopore.
[0027] A system is also provided, which includes:
[0028] - A medium containing light-scattering components;
[0029] - Nanopores in contact with the medium;
[0030] - The medium near the nanopore is illuminated by one or more light sources; and
[0031] - Reference light source.
[0032] In some embodiments, the light-scattering component is non-fluorescent. In some embodiments, the medium contains an analyte for detection. In some embodiments, the system further includes a kinetic protein for controlling the movement of the analyte relative to the nanopore.
[0033] An apparatus for detecting analytes is also provided, comprising:
[0034] - A chamber having a volume containing a medium comprising light-scattering components;
[0035] - A membrane containing nanopores, wherein the nanopores are in contact with the medium;
[0036] - One or more light sources are used to irradiate the volume near the nanopores; and
[0037] - A detector used to detect light scattered by the component.
[0038] In some embodiments, the detector is configured to detect interference between a scattered signal corresponding to the flux of the component through the nanopore and a reference beam. In some embodiments, the medium contains an analyte for detection. In some embodiments, the device further includes a kinetic protein for controlling the movement of the analyte relative to the nanopore. Attached Figure Description
[0039] Figure 1 A schematic diagram of a PMMA microfabricated cover glass sheet that can be used to generate a droplet interface bilayer, as described in the embodiments.
[0040] Figure 2 A schematic diagram of an interference microscope that can be used to implement the claimed method as described in the embodiments.
[0041] Figure 3 A schematic diagram illustrating the detection of scattering from the light-scattering component near the nanopores in the droplet interface bilayer described in the embodiments.
[0042] Figure 4 Montage of α-hemolysin nanopores imaged in the presence of a 1M sucrose gradient without analyte. Results described in the examples.
[0043] Figure 5. Droplet interfacial bilayer, showing point diffraction-limited diffusion of DNA analytes through α-hemolysin nanopores at a voltage-dependent flux (80 mV). 5A: Multiple nanopores. 5B: Time series from a single nanopore in the presence of DNA (50 ms / fr).
[0044] Figure 6 The optical signal generated by interference scattering of the signal through three separate nanopores under the influence of an applied square wave potential (+ / -80mV); each slice corresponds to a 20ms frame.
[0045] Figure 7The optical signal generated by interference scattering of the signal through three separate nanopores under the influence of an applied square wave potential (+ / -200mV). The data are described in Example 2. Detailed Implementation
[0046] This invention will be described with reference to specific embodiments and certain accompanying drawings, but is not limited thereto by the claims. No reference numerals in the claims should be construed as limiting the scope. It should be understood, of course, that not all aspects or advantages can be achieved according to any particular embodiment of the invention. Therefore, for example, those skilled in the art will recognize that the invention may be embodied or practiced in a manner that achieves or optimizes one or more advantages as taught herein, without necessarily achieving other aspects or advantages as may be taught or suggested herein.
[0047] The invention (both in terms of organization and method of operation) and its features and advantages can be best understood by referring to the following detailed description when read in conjunction with the accompanying drawings. Aspects and advantages of the invention will become apparent from one or more embodiments described below, and will be set forth with reference to said embodiments. Throughout this specification, reference to “in one embodiment” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the invention. Therefore, the phrases “in one embodiment” or “in an embodiment” appearing in various places throughout this specification do not necessarily refer to the same embodiment, but may refer to the same embodiment. Similarly, it should be understood that in the description of exemplary embodiments of the invention, various features of the invention are sometimes grouped together in a single embodiment, drawing, or description thereof for the purpose of simplifying this disclosure and aiding in the understanding of one or more of the various inventive aspects. However, the method of this disclosure should not be construed as reflecting an intention to reflect more features required by the claimed invention than expressly recited in each claim. Rather, as reflected in the following claims, the inventive aspect lies in fewer features than all of the features of a single foregoing disclosed embodiment.
[0048] It should be understood that, unless the context otherwise requires, the “implementations” of this disclosure may be specifically combined together. A particular combination of all disclosed embodiments (unless the context otherwise implies) constitutes a further disclosed embodiment of the claimed invention.
[0049] Furthermore, as used in this specification and the appended claims, unless otherwise expressly indicated, the singular forms "a / an" and "the" encompass the plural objects. Thus, for example, a reference to "analyte" includes two or more analytes; a reference to "component" includes two or more such components; a reference to "polynucleotide-binding protein" includes two or more such proteins; a reference to "monomer" refers to two or more monomers; a reference to "pore" includes two or more pores, etc.
[0050] All publications, patents, and patent applications cited in this article, whether mentioned above or below, are incorporated herein by reference in their entirety.
[0051] definition
[0052] When referring to singular nouns (e.g., "a / an", "the"), the use of indefinite or definite articles includes the plural form of the noun unless specifically stated otherwise. The use of the term "comprising" in this specification and claims does not exclude other elements or steps. Furthermore, the terms first, second, third, etc., in the specification and claims are used to distinguish similar elements and are not necessarily used to describe order or chronological sequence. It should be understood that the terms thus used are interchangeable where appropriate, and embodiments of the invention described herein can operate in a different order than that described or illustrated herein. The following terms or definitions are provided only to aid in understanding the invention. Unless specifically defined herein, all terms used herein have the same meaning to those skilled in the art to which this invention pertains. For the definitions and terminology used in this field, practicing physicians have specifically referred to Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 4th edition, Cold Spring Harbor Press, Plainsview, New York (2012); and Ausubel et al., *Current Protocols in Molecular Biology* (Supplement 114), John Wiley & Sons, New York (2016). The definitions provided herein should not be construed as having a scope less than that understood by one of ordinary skill in the art.
[0053] When referring to measurable values such as quantity or duration, the term “about” as used herein means to encompass deviations from the specified value of ±20% or ±10%, more preferably ±5%, even more preferably ±1%, and still more preferably ±0.1%, as such deviations are suitable for performing the disclosed method.
[0054] As used herein, the terms “nucleotide sequence,” “DNA sequence,” or “one or more nucleic acid molecules” refer to a polymer of nucleotides of any length, whether ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Therefore, this term encompasses both double-stranded and single-stranded DNA, as well as RNA. As used herein, the term “nucleic acid” is a single-stranded or double-stranded covalently linked sequence of nucleotides, wherein the 3' and 5' ends of each nucleotide are linked by a phosphodiester bond. Polynucleotides may consist of deoxyribonucleotide bases or ribonucleotide bases. Nucleic acids can be synthesized in vitro or isolated from natural sources. Nucleic acids may further comprise modified DNA or RNA, such as methylated DNA or RNA, or RNA that has undergone post-translational modifications, such as 5' capping with 7-methylguanosine, 3' processing such as cleavage and polyadenylation, and splicing. Nucleic acids can also include synthetic nucleic acids (XNAs), such as hexitol nucleic acid (HNA), cyclohexene nucleic acid (CeNA), threonine nucleic acid (TNA), glycerol nucleic acid (GNA), locked nucleic acid (LNA), and peptide nucleic acid (PNA). The size of a nucleic acid (also referred to herein as a “polynucleotide”) is typically expressed as the number of base pairs (bp) in a double-stranded polynucleotide, or, in the case of a single-stranded polynucleotide, as the number of nucleotides (nt). One thousand bp or nt equals one thousand bases (kb). Polynucleotides shorter than approximately 40 nucleotides are often referred to as “oligonucleotides” and may include primers used for manipulating DNA, such as via polymerase chain reaction (PCR).
[0055] In the context of this disclosure, the term "amino acid" is used in its broadest sense and refers to an organic compound containing amine (NH2) and carboxyl (COOH) functional groups and a side chain (e.g., an R group) specific to each amino acid. In some embodiments, an amino acid refers to a naturally occurring Lα-amino acid or residue. One and three commonly used letter abbreviations for naturally occurring amino acids are used herein: A = Ala; C = Cys; D = Asp; E = Glu; F = Phe; G = Gly; H = His; I = Ile; K = Lys; L = Leu; M = Met; N = Asn; P = Pro; Q = Gln; R = Arg; S = Ser; T = Thr; V = Val; W = Trp; and Y = Tyr (Lehninger, AL, (1975) Biochemistry, 2nd ed., pp. 71-92, Worth Publishers, New York). The general term “amino acid” further includes D-amino acids, trans-amino acids, and chemically modified amino acids, such as amino acid analogs, naturally occurring amino acids that are not typically incorporated into proteins (e.g., ortholeucine), and chemically synthesized compounds that have properties known in the art as amino acid characteristics (e.g., β-amino acids). For example, analogs or mimics of phenylalanine or proline that allow conformational restrictions to the same peptide compounds as natural Phe or Pro are included within the definition of an amino acid. Such analogs and mimics are referred to herein as “functional equivalents” of the corresponding amino acids. Other examples of amino acids are listed by Roberts and Vellaccio, *The Peptides: Analysis, Synthesis, Biology*, edited by Gross and Meiehofer, Vol. 5, p. 341, Academic Press, Inc., NY, 1983, which is incorporated herein by reference.
[0056] The terms “polypeptide” and “peptide” are used interchangeably herein to refer to polymers containing amino acid residues, as well as their variants and synthetic analogs. Therefore, these terms apply to amino acid polymers where one or more amino acid residues are synthetic, non-naturally occurring amino acids, such as chemical analogs of corresponding naturally occurring amino acids, and to polymers containing naturally occurring amino acids. Polypeptides may also undergo maturation or post-translational modification processes, which may include, but are not limited to, glycosylation, proteolytic cleavage, lipolysis, signal peptide cleavage, propeptide cleavage, phosphorylation, etc. Peptides can be prepared using recombinant techniques, for example, by expressing recombinant or synthetic polynucleotides. Recombinant peptides are typically substantially free of culture medium, for example, the culture medium comprises less than about 20% of the protein preparation volume, more preferably less than about 10%, and most preferably less than about 5%.
[0057] The term "protein" is used to describe folded polypeptides that have secondary or tertiary structures. Proteins can consist of a single polypeptide or can comprise multiple polypeptides that assemble to form a multimer. The multimer can be a homooligomer or a heterooligomer. Proteins can be naturally occurring or wild-type proteins, or modified or non-natural proteins. Proteins can differ from wild-type proteins, for example, through the addition, substitution, or deletion of one or more amino acids.
[0058] Protein “variants” encompass peptides, oligopeptides, polypeptides, proteins, and enzymes that have amino acid substitutions, deletions, and / or insertions relative to the unmodified or wild-type protein in question, and possess biological and functional activities similar to those of the unmodified protein from which they are derived. As used herein, the term “amino acid identity” refers to the degree to which sequences are identical on an amino acid-to-amino acid basis within a comparison window. Thus, the “sequence identity percentage” is calculated by comparing two optimally aligned sequences within a comparison window, determining the number of positions in which identical amino acid residues (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys, and Met) appear in both sequences to produce the number of matching positions, dividing the number of matching positions by the total number of positions in the comparison window (i.e., the window size), and multiplying the result by 100 to produce the sequence identity percentage.
[0059] For all aspects and embodiments of the invention, the "variant" has at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% complete sequence identity with the corresponding wild-type protein's amino acid sequence. Sequence identity can also be a fragment or portion of a full-length polynucleotide or polypeptide. Thus, the sequence may have only 50% overall sequence identity with the full-length reference sequence, but the sequence of a specific region, domain, or subunit may share 80%, 90%, or up to 99% sequence identity with the reference sequence.
[0060] The term "wild-type" refers to a gene or gene product isolated from a naturally occurring source. Wild-type genes are the most frequently observed genes in a population and are therefore arbitrarily engineered to be in a "normal" or "wild-type" form. Conversely, the terms "modified," "mutant," or "variant" refer to a gene or gene product that exhibits sequence modifications (e.g., substitution, truncation, or insertion), post-translational modifications, and / or functional characteristics (e.g., altered properties) compared to a wild-type gene or gene product. Note that naturally occurring mutants can be isolated; these mutants are identified by the fact that they possess altered properties compared to a wild-type gene or gene product. Methods for introducing or substituting naturally occurring amino acids are well known in the art. For example, the codon for methionine (ATG) can be substituted with the codon for arginine (CGT) at the relevant position in the polynucleotide encoding the mutant monomer, while methionine (M) is replaced with arginine (R). Methods for introducing or substituting non-naturally occurring amino acids are also well known in the art. For example, non-naturally occurring amino acids can be introduced by including synthetic aminoacyl-tRNA in the IVTT system used to express mutant monomers. Alternatively, this can be introduced by expressing mutant monomers in *E. coli* that are auxotrophic for the specific amino acid in the presence of synthetic (i.e., non-naturally occurring) analogs of those specific amino acids. If the mutant monomer is produced using partial peptide synthesis, it can also be produced via naked linking. Conservative substitution replaces an amino acid with another amino acid having a similar chemical structure, similar chemical properties, or similar side chain volume. The introduced amino acid can have similar polarity, hydrophilicity, hydrophobicity, basicity, acidity, neutrality, or charge as the substituted amino acid. Alternatively, conservative substitution can introduce another aromatic or aliphatic amino acid to replace a pre-existing aromatic or aliphatic amino acid. Conservative amino acid changes are well known in the art and can be selected based on the properties of the 20 major amino acids defined in Table 1 below. In cases where amino acids have similar polarity, this can also be determined with reference to the hydrophilicity scale of the amino acid side chains in Table 2.
[0061] Table 1 - Chemical properties of amino acids
[0062]
[0063] Table 2 - Hydrophilicity Scale
[0064]
[0065] Mutants or modified proteins, monomers, or peptides can also be chemically modified in any manner and at any site. Preferably, mutants or modified monomers are chemically modified by attaching the molecule to one or more cysteine residues (cysteine linkage), attaching the molecule to one or more lysine residues, attaching the molecule to one or more non-natural amino acids, enzymatic modification of epitopes, or terminal modification. Suitable methods for performing such modifications are well known in the art. Mutants of modified proteins, monomers, or peptides can be chemically modified by attaching any molecule. For example, mutants of modified proteins, monomers, or peptides can be chemically modified by linking dyes or fluorophores.
[0066] Methods for detecting analytes
[0067] This disclosure relates to a method for detecting an analyte in a medium. As described above, the method includes generating a flux of a light-scattering component passing through a nanopore and contacting the analyte with the nanopore such that the analyte affects the flux of the component through the nanopore. The medium near the nanopore is irradiated with one or more light sources, causing light to be scattered by the light-scattering component near the nanopore. The analyte is detected when it moves relative to the nanopore by measuring the light scattered by the component.
[0068] It should be understood that light scattered by the light scattering component refers to the scattering of light by the flux of the light scattering component through the nanopore. Therefore, light is scattered by the light scattering component molecules present in the flux of the light scattering component. Therefore, embodiments of the claimed method include one or more measurements of the light scattered by the flux of the light scattering component near the nanopore.
[0069] This method addresses problems associated with known methods for detecting analytes as they move relative to nanopores. For example, as described above, established methods involving the electrical detection of ion currents through nanopores require that each individual nanopore in the array be individually electrically addressable. In contrast, the method provided involves illuminating the vicinity of the nanopores and measuring the scattered light near the nanopores, thus treating each nanopore individually. While in some embodiments, a potential can be used to generate a flux of the light-scattering component through the nanopores, it is not required that each nanopore in the array be individually electrically addressable. Therefore, the method provided is more suitable for parallelization and miniaturization than previously known methods. Furthermore, it is not required that the component used to generate the scattering signal be charged, such that the flux of the component can be driven by the applied potential. While the use of charged components (e.g., driven by voltage) is within the scope of the method provided, these methods are also applicable to generating flux by applying chemical or physical potentials and are applicable to the use of uncharged molecules.
[0070] Another advantage emerges compared to known methods involving fluorescence detection. In the method presented herein, a scattering signal is detected, which can be identified by the flux of the component through the nanopore. The scattering signal is unaffected by photobleaching and is independent of, for example, the quantum yield of the constituent molecules. These methods are unaffected by light saturation. Furthermore, the presented method has the potential to be more sensitive than fluorescence-based methods. The presented method also has the potential to be much faster than fluorescence-based measurements and can be used to record analytes on a timescale of microseconds (μs), rather than the typical milliseconds (ms) of fluorescence-based measurements.
[0071] Another advantage comes from the simplification of the equipment required to put the provided method into practice. In theory, the only equipment needed is a suitable light source for scattering from the component and a detector suitable for detecting the scattered signal. Although the invention is not limited to this, and includes embodiments in which other optics and processors are used to measure the light scattered by the component and thus detect the analyte as it moves relative to the aperture, the simplification of the technique means that it is well-suited for parallelization and miniaturization.
[0072] From the description of the methods provided below, those skilled in the art will understand the further advantages.
[0073] Detection of analytes
[0074] The inventors have discovered that when an analyte moves relative to a nanopore, it can be detected by measuring the light scattered by the light-scattering component near the nanopore once or multiple times.
[0075] Light scattering is a physical phenomenon in which incident light interacts with molecules (referred to herein as the light scattering component) and produces detectable output radiation. The output radiation may have the same or different wavelengths as the incident radiation. As used herein, the term "light" includes both visible wavelengths and infrared and ultraviolet wavelengths, particularly near-infrared and near-ultraviolet wavelengths.
[0076] An example of light scattering is Rayleigh scattering. Rayleigh scattering is primarily elastic scattering caused by particles smaller than the wavelength of the electromagnetic radiation used. In typical operation, the resulting Rayleigh scattering is related to 1 / λ. 4 Proportional, where λ is the wavelength of the scattered radiation.
[0077] The inventors have discovered that many molecules possess suitable molecular cross-sections to induce significant scattering, such as significant Rayleigh scattering, upon exposure to light radiation. In developing the claimed method, the inventors discovered that generating such a flux of molecules through a nanopore and irradiating the vicinity of the nanopore with light radiation results in a scattering signal reporting the state of the nanopore (e.g., the degree to which it is blocked by analyte molecules) in a manner similar to that of charged ions (e.g., K+). + The flow of ions through a nanopore can generate ionic currents that report the state of the nanopore, very similar to those produced by the flow of light through the nanopore. Changes in the scattering signal resulting from the flux of light scattering molecules through the nanopore can be determined and correlated with the state of the nanopore; this, in turn, relates to the properties of the analyte as it moves relative to the nanopore. Therefore, in embodiments of the claimed method, one or more measurements of the light scattered by the component thus include generating a scattering signal corresponding to the flux of the component through the nanopore.
[0078] For example, in some embodiments, a decrease in the scattering signal indicates that the flux of the light-scattering component through the nanopore is blocked by the analyte. Therefore, in some embodiments, detecting a decrease in the scattering signal can correspond to detecting the presence of the analyte. More subtle differences in the scattering signal can be identified by the properties of the analyte. For example, changes in the scattering signal may originate from changes in the analyte structure, such as changes in the nucleotide sequence of a polynucleotide analyte or the peptide sequence of a polypeptide analyte. By monitoring changes in the scattering signal as an analyte, such as a polynucleotide or polypeptide, moves relative to the pore, the properties of the analyte (e.g., the presence or absence of the polynucleotide or polypeptide sequence or modifications thereof) can be determined.
[0079] More specifically, as analyte molecules pass through the channels of the nanopores, they directly and consequently reduce the flux of the light-scattering component through the channels. The flux changes of the light-scattering component can be recorded as described above and correlated with the properties of the analyte. With appropriate calibration, characteristic changes in the flux of the light-scattering component can be used to identify the analyte. For example, in an embodiment of a claimed method in which the analyte is a polynucleotide, the flux changes of the light-scattering component can be correlated with specific nucleotides and associated bases passing through the channels in real time.
[0080] When characterizing analytes using nanopores according to the claimed method, the open-channel flux of the light-scattering component typically decreases as individual molecules of the analyte sequentially pass through the nanopore channels due to partial channel blockage by the analyte. When the analyte is a polymer (e.g., a polynucleotide or peptide), the open-channel flux of the light-scattering component is typically reduced to the number of monomeric units of the analyte (e.g., a single nucleotide unit in a polynucleotide, or a single amino acid in a peptide) sequentially passing through the nanopore channels. This reduction in the flux of the light-scattering component is measured using the scattering signal from the light-scattering component near the nanopore.
[0081] The decrease in flux of the light-scattering component can be calibrated to a decrease in the measured flux of a known substance passing through a nanopore channel, thus creating a device for determining which analyte in a group passes through the channel. For example, the flux decrease caused by a known nucleotide can be correlated with the flux decrease produced when a nucleic acid sequence passes through a nanopore. In this way, the nucleic acid sequence can be determined. When the analyte is a polynucleotide, it should be understood that the complete polynucleotide 'passing through' the pore can be sequenced (e.g., by the action of a relevant polynucleotide-binding protein such as a polymerase or helicase). Alternatively, the sequence can be determined by the passage of triphosphate nucleotide bases that have been sequentially removed from the target nucleic acid analyte near the pore (this process is therefore similar to that discussed in WO2014 / 187924, except that the detection method is according to the method provided herein). Similarly, when a peptide passes through a pore, the sequence of the peptide can be determined by passing amino acids through the pore.
[0082] Typically, the excitation wavelength of the light used to generate scattering is the same as the wavelength of the scattering signal.
[0083] Scattered signal
[0084] The methods provided herein are not limited to any specific scattering signal. Directly recording the scattering signal from the flux of the light scattering component through the nanopore is also within the scope of the methods provided herein. Recording secondary scattering signals, such as the interference signal between the scattering signal and the reference beam, is also within the scope of the methods provided herein. A preferred embodiment of the methods provided herein involves performing one or more measurements on the light scattered by the component by detecting the interference between the scattering signal and the reference beam.
[0085] Any suitable reference beam can be used. For example, the reference beam can be a secondary source. The reference beam can be part of a source that provides a scattered beam. For example, a source for providing an illumination beam can be divided using suitable optics to form a reference beam and a beam for illuminating the medium near the nanopore. Optics suitable for the protected method are described in more detail herein. Optics suitable for the claimed method typically include one or more mirrors, one or more acousto-optic deflectors, one or more polarizing beam splitters, and / or one or more quarter-wave plates, etc.
[0086] In the presence of a reference beam and a scattered beam, an interferometer can be used to detect the interference signal between the scattered beam and the reference beam. Optical configurations capable of detecting interference between these two beams are well known. For example, two-path or co-path interferometry methods such as Michelson, Mach-Zehnder, or Sagnac configurations can be used to detect interference.
[0087] In some implementations, the reference beam is provided as a reflected beam. The reflected beam can be reflected from any suitable surface or interface. For example, when nanopores are present in a membrane, the reference beam can be reflected from the surface of the membrane. The reference beam can be reflected from the surface of a solid support, such as a support used for a membrane. The reference beam can be reflected from the surface of a droplet, such as a droplet forming a droplet interfacial bilayer.
[0088] A reference beam can be reflected from an interface. An interface can be between a membrane and a medium containing the analyte. An interface can be between a solid support and a membrane. An interface can be between a droplet and a solid support or another droplet, for example, in a droplet interfacial bilayer.
[0089] Typically, the reference beam is focused at or near the nanopores; for example, it can be focused at an interface, such as on a membrane in which nanopores exist. The focus of the reference beam is generally unaffected by any fluid disturbances in the system, and devices for minimizing fluid disturbances can be used.
[0090] Irradiation and Measurement
[0091] The methods described herein involve illuminating a medium near a nanopore with one or more light sources. As used herein, unless the context otherwise suggests, the terms “illuminate” and “irradiate” are synonyms.
[0092] Depending on the parameters and settings of the device used in the method, any suitable light source can be used. The sensitivity of the disclosed method is a parameter that can be controlled by selecting a light source with appropriate spatial and temporal coherence.
[0093] For those skilled in the art, selecting a suitable light source is conventional. In some embodiments, one or more light sources independently include lasers, superluminescent diodes, and / or incoherent sources. In some embodiments, a suitable incoherent light source used in the claimed method is an LED or a lamp. In some embodiments, only one light source is used. In some embodiments, more than one, such as two, three, or four, for example, two light sources, may be used. In embodiments that include the claimed method using more than one light source, the light sources may be the same or different. For example, one or more light sources may include one or more lasers, one or more superluminescent diodes, and / or one or more incoherent sources. For example, one or more light sources may include two or more lasers and optional additional light sources, such as one or more superluminescent diodes and / or one or more incoherent sources.
[0094] In some implementations, the light source includes one or more lasers. Suitable lasers include diode lasers that operate at wavelengths from, for example, from about 400 nm to about 800 nm, or from, for example, from about 450 nm to about 700 nm. Exemplary lasers may operate at, for example, 445 nm, 473 nm, 532 nm, 639 nm, 662 nm, etc. Suitable power densities for laser irradiation include those from about 1 kW / cm². 2 Up to approximately 30kW / cm 2 The power density, for example, is from about 5 kW / cm². 2 Up to approximately 20kW / cm 2 For example, from about 10 kW / cm 2 Up to approximately 15kW / cm 2 For example, approximately 13 kW / cm 2 Suitable lasers can be obtained from companies such as Coherent in the United States.
[0095] Scattering of light from the light scattering component can be detected using any suitable method or device. For example, a CCD (charge-coupled device) camera, a CMOS (complementary metal-oxide-semiconductor) camera, or a point detector such as a photodiode can be used to detect scattering. CCD and CMOS detectors and photodiodes are commercially available, for example, from suppliers such as PhotonFocus AG of Sweden. Those skilled in the art will be able to readily select a suitable detector (e.g., CCD, CMOS, or photodiode) for detecting light scattering according to the claimed method.
[0096] The exemplary methods provided herein include detecting interference between a scattered signal and a reference signal, but not detecting the scattered signal and / or the reference signal itself. However, the methods provided herein also include detecting the scattered signal itself using a detector. In methods that include detecting the scattered signal itself, the reference signal itself may also optionally be detected. If present, the reference signal is typically detected by the same detector used to detect the scattered signal. For example, a detector selected from CCDs, CMOS cameras, and point detectors such as photodiodes can be used to detect the scattered signal and the reference beam (if present) and / or the interference between them. The detected signal (e.g., a signal generated by interference between the scattered signal and the reference signal, or the scattered signal itself and the reference signal (if present)) can then be processed, for example, by software.
[0097] In embodiments of the claimed method that includes detecting interference between a scattered signal and a reference beam, interference can be detected by means of methods such as reflection contrast interferometry, digital holographic interferometry, interferometric scattering microscopy (iSCAT), or coherent bright-field interferometry (COBRI). Such techniques are familiar to those skilled in the art. iSCAT is described, for example, in Wit et al., Proceedings of the National Academy of Sciences USA, 6 (2015) 12299-12303, which applies the technique to dynamic label-free imaging of lipid nanodomains. Coherent bright-field interferometry (COBRI) is described in Cheng et al., Nanoscale, 11 (2019) 568-577. Reflection contrast interferometry is described in Weber, Methods in Enzymology, 361 (2003) 34-47. Digital holographic interferometry is described in Kim, “Digital Holographic Microscopy”, 2011 (162), Springer-Verlag New York. The examples provided herein demonstrate the use of appropriate methods to detect scattering from light scattering components.
[0098] In some implementations, interference is detected by iSCAT. In some implementations, suitable equipment for performing iSCAT measurements includes one or more lasers as described herein, optionally passing through one or more, for example, two acousto-optic deflectors (AODs), which can be scanned at, for example, sawtooth waves of 79 and 80 kHz respectively. Relative and absolute frequencies can be selected to minimize detectable fluctuations in background light intensity over the timescale of camera exposure time. The beam deflected by the AOD can be imaged, for example, using a telecentric lens. The beam can be passed through a polarization beam splitter. A quarter-wave plate (QWP) can be used to convert P-polarized incident light to S-polarized light.
[0099] The method presented herein involves generating a flux of a component through a nanopore. The nanopore is in contact with a medium containing a light-scattering component, and the method includes performing one or more measurements on the light scattered by the component near the nanopore.
[0100] Typically, the flux of a component through a nanopore is the flux from the medium in a first volume to the medium in a second volume. For example, the medium in the first volume can be a "cis" volume, and the medium in the second volume can be a "reverse" volume; the symbols "cis" and "reverse" are conventional in the art and reflect the voltage typically applied across the nanopore in conventional methods (a cis volume is typically a volume containing a negatively charged electrode, and a reverse chamber is a volume containing a positively charged electrode, thus allowing a voltage to be applied across the nanopore). The medium in the first volume can be the same as or different from the medium in the second volume. For example, the medium in the first volume can have a different pH, concentration, or contain different components than the medium in the second volume.
[0101] In some embodiments, the medium in the first volume may have a different refractive index than the medium in the second volume. In such embodiments, the medium flux from the first volume to the second volume allows for the recording of scattered signals. Any suitable difference between the media in the first and second volumes that causes a change in refractive index between the media can be used. For example, the composition of the medium in the first volume may differ from that in the second volume.
[0102] In some implementations, the concentration of the light-scattering component in the first volume differs from the concentration of the light-scattering component in the second volume; for example, the concentration of the light-scattering component in the first volume may be higher than the concentration of the light-scattering component in the second volume. This concentration difference can provide a gradient for generating the flux of the light-scattering component from the first volume to the second volume.
[0103] Typically, the flux of the light-scattering component is from the medium in the first volume to the medium in the second volume, and one or more measurements of the light scattered by the component are one or more measurements of the medium in the second volume near the nanopore. In such embodiments, the concentration of the light-scattering component in the first volume is typically excessive compared to the second volume. Therefore, the flux of the light-scattering component from the first volume to the second volume usually does not significantly change the concentration of the light-scattering component in the first volume, while the concentration in the second volume, particularly near the nanopore connecting the first and second volumes, is significantly altered by the flux of the light-scattering component. The advantage of this is that the scattering signal generated by the light-scattering component is therefore highly responsive to the flux of the light-scattering component from the first volume to the second volume. This allows for precise monitoring of the interaction between the analyte and the nanopore by monitoring changes in the scattering signal caused by interference of the analyte with the flux of the light-scattering component.
[0104] In some embodiments, irradiating the medium near the nanopore includes irradiating a first volume without irradiating a second volume, or vice versa. In some embodiments, performing one or more measurements of the light scattered by the components near the nanopore includes performing the one or more measurements of the light scattered in the first volume but not in the second volume, or vice versa.
[0105] Those skilled in the art will understand that a reverse setup is also possible, wherein the flux of the light-scattering component is from the medium of the second volume to the medium of the first volume, and one or more measurements of the light scattered by the component are one or more measurements of the medium of the first volume near the nanopore.
[0106] The method described herein involves illuminating a medium near a nanopore with one or more light sources and performing one or more measurements of the light scattered by light-scattering components near the nanopore as the analyte moves relative to the nanopore. The appropriate volume to be measured will be determined by those skilled in the art based on the experimental parameters used, such as the light-scattering components in the medium and the diffusion coefficient of the analyte, the wavelength of the light used to irradiate the medium near the nanopore, and the characteristics of the analyte to be measured.
[0107] As a non-limiting example, in some embodiments, the method includes irradiating a medium in a volume extending less than 1000 μm from a nanopore, for example, less than 100 μm, less than 10 μm, less than 5 μm, less than 2 μm, or about 1 μm from a nanopore. In some embodiments, the method includes irradiating a medium in a volume surrounding a nanopore, wherein the volume is defined by the diffusion coefficient of a light-scattering component in the medium.
[0108] Typically, the components that can be used to generate scattering signals according to the method provided herein have a size of approximately μm. 2 3D diffusion coefficients on the order of μs. For example, the diffusion coefficient of sucrose in water is approximately 520 μm. 2 / s. The volume can be defined as the square radius having, for example, at most 1x, at most 0.5x, at most 0.1x, at most 0.05x, or at most 0.01x of the diffusion coefficient of the light scattering component in the medium. Choosing an appropriate irradiation volume is a parameter that can be optimized by those skilled in the art, depending on the equipment and experimental setup used. Generally, an appropriate volume is chosen to maximize sensitivity and temporal resolution; as the irradiation volume decreases, sensitivity typically decreases, but temporal resolution increases.
[0109] Light scattering components
[0110] As described in more detail herein, the method provided herein includes detecting an analyte in a medium by measuring light scattered by a light-scattering component near the nanopore as the analyte moves relative to the nanopore.
[0111] The light-scattering component has a refractive index. The medium also has a refractive index. The refractive indices of the light-scattering component and the medium are determined by their respective components.
[0112] To enhance light scattering, it is useful for the light-scattering component to have a refractive index different from that of the medium. Typically, in embodiments of the methods provided herein, the refractive index of the light-scattering component is greater than that of the medium. However, in other embodiments, the refractive index of the light-scattering component is less than that of the medium.
[0113] Any suitable light scattering component can be used in the method provided herein, and the selection of a suitable light scattering component will be obvious to those skilled in the art.
[0114] Typically, in the methods provided herein, the light-scattering component is a hydrophilic, water-soluble molecule. Any suitable molecule can be used. Generally, the light-scattering component is an uncharged, hydrophilic, water-soluble molecule. However, in some embodiments, the light-scattering component is a non-water-soluble molecule; this is particularly useful when the medium is non-aqueous, such as an organic solvent.
[0115] Examples of suitable molecules for use as light-scattering components include hydrocarbons, solvents, organic molecules such as carbohydrates, amino acids (including oligopeptides and polypeptides), sugars (including oligosaccharides and polysaccharides), nucleic acids (e.g., polynucleotides), non-biological polymers, salts and other electrolytes, amphiphiles, and surfactants. For example, light-scattering components may include or consist of: liquid hydrocarbons, such as oils or other solvents (e.g., benzene), including alcohols (e.g., ethanol, isopropanol, etc.), ketones (e.g., acetone), aldehydes, esters, perfluorinated carbon, etc. Light-scattering components may include or consist of: polymers, such as alkylene glycols (e.g., ethylene glycol) and fluoropolymers (e.g., CYTOP available from AGC Chemicals Company). (R) The light-scattering component may include or consist of linear or branched sugars such as monosaccharides, disaccharides, oligosaccharides, and polysaccharides. Examples include sucrose, lactose, maltose, dextrose, trehalose, glucose, ficoll, etc. Sucrose is particularly suitable for the methods described herein. Other substances suitable as light-scattering components include nucleic acids, silicone oils, amphiphiles, and surfactants such as polysorbates (e.g., TWEENs, available from Sigma Aldrich), sterols, etc.; the method is extended to use light-scattering components such as supercritical CO2. In some preferred embodiments, the light-scattering component comprises or is composed of sugars or polyethylene glycols. In some embodiments, the light-scattering component comprises sucrose.
[0116] Obviously, the choice of light-scattering component will depend on the medium used. For example, the light-scattering component needs to be soluble in the medium. Therefore, in one embodiment, the medium is an aqueous medium and the light-scattering component is a water-soluble molecule, such as the molecules described above. In some embodiments, the component is not fluorescent (i.e., it is non-fluorescent). In some embodiments, the light-scattering component does not consist of or contains fluorophores.
[0117] As described above, the claimed method involves generating a flux of light-scattering components through a nanopore. This flux can be driven by a free energy gradient, such as a physical or chemical potential across the nanopore. In some embodiments, the flux of the light-scattering components is directly driven by a physical force provided by an electric potential (e.g., voltage) or indirectly driven by the like, such as a temperature gradient. In some embodiments, the flux of the light-scattering components is indirectly driven by a chemical potential provided by a concentration (e.g., pH) gradient across the nanopore.
[0118] For example, in an embodiment of the claimed method for generating a flux of light-scattering components between a first volume and a second volume, the concentration of the light-scattering component in the first volume may be higher than the concentration of the light-scattering component in the second volume, thereby providing a concentration gradient of the light-scattering component between the first and second volumes. When the first and second volumes are connected by nanopores, the flux of the light-scattering component will increase from the first volume to the second volume.
[0119] In other embodiments where a flux of light-scattering component is generated between the first and second volumes, the light-scattering component can be charged and a potential can be applied across the membrane separating the first and second volumes. The charge on the light-scattering component causes it to move under the applied potential (e.g., voltage). When the first and second volumes are connected by a nanopore, the flux of the light-scattering component will increase from the first volume to the second volume. For example, if a positive voltage potential is applied relative to the cis side of the nanopore to the anti-cis side, this will induce a negatively charged light-scattering component to move from the cis side to the anti-cis side. Similarly, if a positive voltage potential is applied relative to the cis side of the nanopore to the anti-cis side, this will prevent a negatively charged light-scattering component from moving from the anti-cis side to the cis side. The opposite occurs if a negative voltage potential is applied relative to the cis side of the nanopore to the anti-cis side. Apparatus and methods for applying appropriate voltages are described in more detail herein.
[0120] Analytes
[0121] The detection of molecules, such as biomolecules, and the characterization of the detected (bio)molecules can be applied to personalized medicine development, medicine, diagnostics, life science research, environmental monitoring, and the safety and / or defense industries. Therefore, the methods described herein are applied in at least these industries.
[0122] The methods described herein can be used to detect any suitable analyte. Suitable analytes include, but are not limited to, metal ions, inorganic salts, polymers such as polymeric acids or bases, dyes, bleaching agents, pharmaceuticals, diagnostic reagents, recreational drugs, explosives, and environmental pollutants. The methods described herein can be used to beneficially analyze or characterize such analytes.
[0123] In some implementations, the analyte is secreted by the cell. Alternatively, the analyte may be present inside the cell such that it must be extracted from the cell. The analyte is typically a polymer. The analyte may be charged. The analyte may be positively or negatively charged, but is typically negatively charged. The analyte may be uncharged, and is typically a biopolymer. The analyte is typically a polynucleotide, polypeptide, or polysaccharide, more commonly a polynucleotide or polypeptide, with polynucleotides being the most common.
[0124] The analytes characterized in the methods described herein may be provided as an impure mixture of one or more target analytes and one or more impurities. Impurities may include truncated forms of target polynucleotides or peptide analytes that differ from the target analytes. For example, the target analyte may be genomic DNA, and impurities may include portions of genomic DNA, plasmids, etc. Target polynucleotides may be coding regions of genomic DNA, and unwanted polynucleotides may include non-coding regions of DNA.
[0125] In one implementation, the analyte is a polynucleotide (a large molecule consisting of two or more nucleotides). Nucleic acid bases naturally present in DNA and RNA can be distinguished by their physical size.
[0126] Polynucleotides, or nucleic acids, can include any combination of any nucleotides. Nucleotides can be naturally occurring or artificial. One or more nucleotides in a polynucleotide can be oxidized or methylated. One or more nucleotides in a polynucleotide can be damaged. For example, polynucleotides can include pyrimidine dimers. Such dimers are commonly associated with UV damage and are a major cause of melanoma.
[0127] One or more nucleotides in a polynucleotide may be modified, for example, by a tag or label, suitable examples of which are known to those skilled in the art. A polynucleotide may include one or more spacers. Adaptors, such as sequencing adaptors, may be included in a polynucleotide. Adaptors, tags, and spacers are described in more detail herein.
[0128] Nucleotides typically contain a nucleobase, a sugar, and at least one phosphate group. The nucleobase and sugar form a nucleoside. The nucleobase is typically heterocyclic. Nucleobases include, but are not limited to, purines and pyrimidines, and more specifically, adenine (A), guanine (G), thymine (T), uracil (U), and cytosine (C). The sugar is typically a pentose sugar. Nucleotide sugars include, but are not limited to, ribose and deoxyribose. The sugar is preferably deoxyribose. Polynucleotides preferably include the following nucleosides: deoxyadenosine (dA), deoxyuridine (dU), and / or thymidine (dT), deoxyguanosine (dG), and deoxycytidine (dC). Nucleotides are typically ribonucleotides or deoxyribonucleotides. Nucleotides typically contain monophosphate, diphosphate, or triphosphate. Nucleotides may include more than three phosphates, such as four or five phosphates. Phosphates may be attached to the 5' or 3' side of the nucleotide. Nucleotides in a polynucleotide may be linked to each other in any manner. Nucleotides are typically linked by their sugar and phosphate groups, as in nucleic acids. Nucleotides can also be linked by their nucleobases, as in pyrimidine dimers. Polynucleotides can be single-stranded or double-stranded. At least a portion of a polynucleotide is preferably double-stranded. Polynucleotides are most preferably ribonucleic acid (RNA) or deoxyribonucleic acid (DNA). In particular, when the analyte being evaluated using the methods provided herein is a polynucleotide, the methods typically involve determining one or more of the following characteristics: (i) the length of the polynucleotide; (ii) the homogeneity of the polynucleotide; (iii) the sequence of the polynucleotide; (iv) the secondary structure of the polynucleotide; and (v) whether the polynucleotide is modified.
[0129] Polynucleotides can be of any length (i). For example, the length of a polynucleotide can be at least 10, at least 50, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, or at least 500 nucleotides or nucleotide pairs. The length of a polynucleotide can be 1000 or more nucleotides or nucleotide pairs, 5000 or more nucleotides or nucleotide pairs, or 100,000 or more nucleotides or nucleotide pairs. Any number of polynucleotides can be studied. For example, methods can involve characterizing 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 50, 100, or more polynucleotides. If two or more polynucleotides are characterized, they can be different polynucleotides or two examples of the same polynucleotide. Polynucleotides can be naturally occurring or artificial. For example, methods can be used to verify the sequence of a manufactured oligonucleotide. Methods are typically performed in vitro.
[0130] Nucleotides can have any identity (ii) and include, but are not limited to, adenosine monophosphate (AMP), guanosine monophosphate (GMP), thymidine monophosphate (TMP), uridine monophosphate (UMP), 5-methylcytidine monophosphate, 5-hydroxymethylcytidine monophosphate, cytidine monophosphate (CMP), cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), deoxyadenosine monophosphate (dAMP), deoxyguanosine monophosphate (dGMP), deoxythymidine monophosphate (dTMP), deoxyuridine monophosphate (dUMP), deoxycytidine monophosphate (dCMP), and deoxymethylcytidine monophosphate. The nucleotide is preferably selected from AMP, TMP, GMP, CMP, UMP, dAMP, dTMP, dGMP, dCMP, and dUMP. Nucleotides can be baseless (i.e., lacking a nucleobase). Nucleotides may also lack a nucleobase and a sugar (i.e., be a C3 spacer). The sequence of nucleotide (iii) is determined by the sequential identity of the following nucleotides attached to each other in the 5' to 3' direction of the chain throughout the polynucleotide strain.
[0131] Target polynucleotides may include products of PCR reactions, genomic DNA, products of endonuclease digestion, and / or DNA libraries. Target polynucleotides can be obtained or extracted from any organism or microorganism. Target polynucleotides are typically obtained from humans or animals, such as from urine, lymph, saliva, mucus, semen, or amniotic fluid, or from whole blood, plasma, or serum. Target polynucleotides may be obtained from plants, such as cereals, legumes, fruits, or vegetables. Target polynucleotides may contain genomic DNA. Genomic DNA may be fragmented. DNA fragmentation can be performed by any suitable method. For example, methods for fragmenting DNA are known in the art, and such methods may use transposases, such as MuA transposase. Often, genomic DNA is not fragmented. In some embodiments, target polynucleotides may be DNA, RNA, and / or DNA / RNA hybrids.
[0132] When the analyte is a polynucleotide, it can be single-stranded or double-stranded. Typically, when the analyte is a polynucleotide, it is single-stranded, such as cDNA or RNA.
[0133] The analyte may be a polypeptide. A polypeptide may be a protein or a fragment thereof. A polypeptide may be naturally occurring or non-natural. A polypeptide may include synthetic or modified amino acids. Many different types of modifications to amino acids are known in the art. Suitable amino acids and their modifications are discussed herein. For the purposes of this invention, it should be understood that polypeptides can be modified by any method available in the art. For example, polypeptides can be modified by post-translational modification or by sequence variations produced by alternative splicing of RNA during biopeptide synthesis.
[0134] When the analyte is a polypeptide, the polypeptide can be a polypeptide secreted from cells. Alternatively, the polypeptide can be a polypeptide present inside cells, so that the polypeptide must be extracted from cells before the present invention can be carried out. It can be extracted by using antibodies or by binding to an affinity tag introduced on the protein.
[0135] As used herein, a polypeptide can be a shorter peptide, typically a polymer of about 2 to about 50 amino acids, or it can be a longer polymer of amino acids. A protein is typically a polypeptide that folds into a functional conformation or forms part of a functional complex.
[0136] When the analyte is a peptide, any peptide can be used. Suitable peptides include, but are not limited to, proteins such as enzymes, antibodies, hormones, growth factors, or growth regulators such as cytokines; or fragments of such proteins. Peptides can be bacterial, archaea, fungal, viral, or parasite-derived. Peptides can be plant-derived. Peptides are typically mammalian, and more commonly human.
[0137] The analyte can be a polysaccharide. A polysaccharide is a polymeric carbohydrate molecule composed of chains of monosaccharide units linked together by glycosidic bonds. Polysaccharides can be linear or branched. They can be homogeneous (containing only one repeating unit) or heterogeneous (containing modifications to the repeating unit). Polysaccharides include callose or laminarin, golden fern polysaccharides, xylan, arabinoxylan, mannan, fucoidan, and galactomannan.
[0138] The analyte can be a polysaccharide produced by bacteria, such as pathogens. The polysaccharide can be a capsular polysaccharide with a molecular weight of 100-2000 kDa. The polysaccharide can be synthesized from a nucleotide-activated precursor (called a nucleotide sugar). The polysaccharide can be a lipopolysaccharide. The polysaccharide can be a therapeutic polysaccharide. The polysaccharide can be a toxic polysaccharide. The polysaccharide can be suitable for use as a vaccine. The polysaccharide can be, for example, bacterial or plant-derived. The polysaccharide can be used as an antibiotic, such as streptomycin, neomycin, paromomycin, kanamycin, chamomycin, erythromycin, dacryomycin, spiramycin, pyruvicin, erythromycin, and cymomycin, or derivatives of any of the aforementioned compounds.
[0139] Labeling analytes with molecular markers is within the scope of the methods provided herein. Molecular markers can modify analytes, facilitating their detection in the methods provided herein. For example, a marker can modify an analyte to alter, for instance, the degree to which the analyte's light-scattering interference components pass through the nanopores. In this way, labeling can improve the sensitivity of the method.
[0140] In some embodiments, the analyte contains an optical marker, such as a fluorescent marker. However, in other embodiments, the analyte is not marked, for example, it is not marked with an optical marker. In some embodiments, the analyte does not contain an optical marker, such as a fluorophore or chromophore. In some embodiments, the analyte is not fluorescently marked.
[0141] connector
[0142] In some embodiments of the methods provided herein, the analyte to be detected is a polynucleotide (“target polynucleotide”). In some embodiments, a polynucleotide adaptor may be attached to the target polynucleotide to characterize the target polynucleotide. The adaptor typically comprises a polynucleotide chain capable of attaching to the end of the target polynucleotide.
[0143] An adaptor can be attached to only one end of the target polynucleotide. Alternatively, a polynucleotide adaptor can be added to both ends of the target polynucleotide. Or, different adaptors can be added to both ends of the target polynucleotide.
[0144] An adaptor can be added to both strands of a double-stranded polynucleotide. An adaptor can also be added to only one strand of a polynucleotide. Methods for adding an adaptor to a polynucleotide are known in the art. The adaptor can be linked to the polynucleotide, for example, by ligation, by click chemistry, by labeling, by topoisomerization, or by any other suitable method.
[0145] In one embodiment, the adaptor or each adaptor is synthetic or artificial. Typically, the adaptor or each adaptor comprises a polymer as described herein. In some embodiments, the adaptor or each adaptor comprises a spacer as described herein. In some embodiments, the adaptor or each adaptor comprises a polynucleotide. The polynucleotide adaptor or each polynucleotide adaptor may comprise DNA, RNA, modified DNA (e.g., base-free DNA), RNA, PNA, LNA, BNA, and / or PEG. Typically, the adaptor or each adaptor comprises single-stranded and / or double-stranded DNA or RNA. The adaptor may comprise a polynucleotide of the same type as the polynucleotide chain to which it is attached. The adaptor may contain a polynucleotide of a different type than the polynucleotide chain to which it is attached. In some embodiments, the polynucleotide chain evaluated and characterized in the methods described herein is a double-stranded DNA chain and the adaptor comprises DNA or RNA, such as double-stranded or single-stranded DNA.
[0146] In some embodiments, the adaptor can be a bridging moiety. The bridging moiety can be used to connect the two strands of a double-stranded polynucleotide. For example, in some embodiments, the bridging moiety is used to connect the template strand of the double-stranded polynucleotide to its complementary strand.
[0147] The bridging portion typically covalently links the two strands of the target polynucleotide. The bridging portion can be anything capable of linking the two strands of the target polynucleotide, provided that it does not interfere with the movement of the single-stranded polynucleotide through the transmembrane pore. Suitable bridging portions include, but are not limited to, polymeric linkers, chemical linkers, polynucleotides, or peptides. Preferably, the bridging portion includes DNA, RNA, modified DNA (e.g., baseless DNA), RNA, PNA, LNA, or PEG. More preferably, the bridging portion is DNA or RNA.
[0148] In some embodiments, the bridging portion is a hairpin adaptor. A hairpin adaptor is an adaptor comprising a single polynucleotide chain, wherein the ends of the polynucleotide chains are capable of hybridizing to or being hybridized to each other, and wherein the middle segment of the polynucleotide forms a loop. Suitable hairpin adaptors can be designed using methods known in the art. In some embodiments, the length of the hairpin loop is typically 4 to 100 nucleotides, for example 4 to 50, 4 to 20, or 4 to 8 nucleotides. In some embodiments, the bridging portion (e.g., the hairpin adaptor) is attached to one end of the target polynucleotide. The bridging portion (e.g., the hairpin adaptor) is typically not attached to either end of the target polynucleotide.
[0149] In some implementations, the adaptor is a linear adaptor. A linear adaptor can bind to either or both ends of a single-stranded polynucleotide. When the polynucleotide is a double-stranded polynucleotide, the linear adaptor can bind to either or both ends of either strand or both strands of the double-stranded polynucleotide. The linear adaptor may include a leader sequence as described herein. The linear adaptor may include a portion for hybridization with a tag (such as a pore tag) as described herein. The length of the linear adaptor can be from 10 to 150 nucleotides, such as 20 to 120, 30 to 100, 40 to 80, or 50 to 70 nucleotides. The linear adaptor can be single-stranded. The linear adaptor can be double-stranded.
[0150] In some implementations, the adaptor may be a Y-adaptor. A Y-adaptor is typically a polynucleotide adaptor. A Y-adaptor is typically double-stranded and includes (a) a region at one end where the two strands hybridize, and (b) a region at the other end where the two strands are not complementary. The non-complementary portions of the strands typically form overhangs. The presence of non-complementary regions in the Y-adaptor gives it a Y-shape because the two strands are not typically non-hybridized to each other as in a double-stranded portion. The two single-stranded portions of the Y-adaptor may be of the same length or different lengths. For example, one single-stranded portion of the Y-adaptor may be 10 to 150 nucleotides long, such as 20 to 120, 30 to 100, 40 to 80, or 50 to 70 nucleotides long, and the other single-stranded portion of the Y-adaptor may independently be 10 to 150 nucleotides long, such as 20 to 120, 30 to 100, 40 to 80, or 50 to 70 nucleotides long. The length of the double-stranded "stem" portion of the Y-connector can be, for example, 10 to 150 nucleotides, such as 20 to 120, 30 to 100, 40 to 80, or 50 to 70 nucleotides.
[0151] The adaptor can be linked to the target polynucleotide by any suitable method known in the art. The adaptor can be synthesized separately and linked to the target polynucleotide chemically or enzymatically. Alternatively, the adaptor can be generated during the processing of the target polynucleotide. In some embodiments, the adaptor is linked to the target polynucleotide at or near one end of the target polynucleotide. In some embodiments, the adaptor is linked to the target polynucleotide within 50 nucleotides, such as within 20 nucleotides, or even within 10 nucleotides from the end of the target polynucleotide. In some embodiments, the adaptor is linked to the target polynucleotide at its end. When the adaptor is linked to the target polynucleotide, the adaptor may comprise a nucleotide of the same type as the target polynucleotide or may comprise a nucleotide different from the target polynucleotide.
[0152] Label
[0153] In some embodiments of the methods provided herein, the analyte to be detected is a polynucleotide (“target polynucleotide”). In some embodiments, for example, tags on the nanopores may be used to facilitate the capture of the analyte polynucleotide by the nanopores.
[0154] The interaction between the tag on the nanopore and the binding site on the polynucleotide (e.g., a binding site present in the adaptor attached to the polynucleotide, wherein the binding site may be provided by the anchor or leader sequence of the adaptor or by the capture sequence within the double-stranded stem of the adaptor) can be reversible. For example, the polynucleotide can bind to the tag on the nanopore, for example, through its adaptor, and be released at certain points, for example, during characterization of the polynucleotide through the nanopore and / or during polymerase processing. Strong nonvalent binding (e.g., biotin / avidin) remains reversible and can be used in some embodiments of the methods described herein. For example, to ensure that the complement of the double-stranded polynucleotide is processed after template treatment, it is desirable to design a pair of pore tags and polynucleotide adaptors to provide sufficient interaction between the complement of the double-stranded polynucleotide (or the complement-linked portion of the adaptor) and the nanopore, such that the complement remains close to the nanopore (without dissociating from and diffusing from the nanopore) but is able to be released from the nanopore upon processing.
[0155] The pore tag and polynucleotide adaptor can be configured such that the binding strength or affinity of the binding site on the polynucleotide (e.g., a binding site provided by the anchor or leader sequence of the adaptor or by a capture sequence within the double-stranded stem of the adaptor) to the tag on the nanopore is sufficient to maintain the connection between the nanopore and the polynucleotide until an applied force is applied thereto release the bound polynucleotide from the nanopore. In some embodiments where the analyte is a double-stranded polynucleotide, the applied force can be the complementary strand processed by a polymerase.
[0156] In some implementations, the tag or tether is uncharged. This ensures that the tag or tether will not be pulled into the nanopore under the influence of a potential difference (if present).
[0157] One or more molecules that attract or bind to polynucleotides or adaptors can be attached to a detector (e.g., a pore). Any molecule that hybridizes to the adaptor and / or target polynucleotide can be used. The molecules attached to the pore can be selected from PNA tags, PEG linkers, short oligonucleotides, positively charged amino acids, and aptamers. Pores with such molecules attached to them are known in the art. For example, pores with short oligonucleotides attached thereto are disclosed in Howarka et al. (2001), Nature Biotech, 19:636-639 and WO 2010 / 086620, and pores including PEG attached to the lumen of the pore are disclosed in Howarka et al. (2000), J.Am.Chem.Soc., 122(11):2411-2416.
[0158] Short oligonucleotides attached to nanopores include sequences complementary to a leader sequence in an adaptor or another single-stranded sequence, which can be used to enhance the capture of target polynucleotides in the methods described herein.
[0159] In some embodiments, the tag or tie may comprise or may be an oligonucleotide (e.g., DNA, RNA, LNA, BNA, PNA, or morpholino). The oligonucleotide may be about 10-30 nucleotides long or about 10-20 nucleotides long. In some embodiments, the oligonucleotide may have at least one end (e.g., a 3' or 5' end) modified for conjugation to other modified or solid substrate surfaces (including, for example, beads). The end modifier may add reactive functional groups that can be used for conjugation. Examples of functional groups that can be added include, but are not limited to, amino, carboxyl, thiol, maleimide, aminooxy, and any combination thereof. The functional group may be combined with spacers of different lengths (e.g., C3, C9, C12, spacer 9, and 18) to increase the physical distance between the functional group and the end of the oligonucleotide sequence.
[0160] Examples of modifications on the 3' and / or 5' ends of oligonucleotides include, but are not limited to, 3' affinity tags and functional groups for chemical linking (including, for example, 3'-biotin, 3'-primary amine, 3'-disulfide amide, 3'-pyridyl disulfide, and any combination thereof); 5' end modifications (including, for example, 5'-primary amine and / or 5'-fluorescein); modifications for click chemistry (including, for example, 3'-azide, 3'-alkynyl, 5'-azide, 5'-alkynyl) and any combination thereof.
[0161] In some embodiments, the tag or linker may further include a polymer linker, for example, to facilitate coupling to the nanopore. Exemplary polymer linkers include, but are not limited to, polyethylene glycol (PEG). The molecular weight of the polymer linker can be from about 500 Da to about 10 kDa (including end values), or from about 1 kDa to about 5 kDa (including end values). The polymer linker (e.g., PEG) can be functionalized with different functional groups, including, for example, but not limited to, maleimide, NHS ester, dibenzocyclooctylene (DBCO), azide, biotin, amine, alkyne, aldehyde, and any combination thereof.
[0162] Other examples of tags or chains include, but are not limited to, His tags, biotin or streptavidin, antibodies that bind to analytes, aptamers that bind to analytes, analyte-binding domains such as DNA-binding domains (including, for example, peptide zippers, such as leucine zippers, single-stranded DNA-binding proteins (SSBs)) and any combination thereof.
[0163] Tags or tethers can be attached to the outer surface of a nanopore, for example, on the cis side of a membrane, using any method known in the art. For example, one or more tags or tethers can be attached to the nanopore via one or more cysteine residues (cysteine bonds), one or more primary amines (such as lysine), one or more non-natural amino acids, one or more histidine residues (His tags), one or more biotin or streptavidin residues, one or more antibody-based tags, one or more enzymatic modifications of epitopes (including, for example, acetyltransferases), and any combination thereof. Suitable methods for making such modifications are well known in the art. Suitable non-natural amino acids include, but are not limited to, 4-azido-L-phenylalanine (Faz), and Liu C.C. and Schultz PG, *Annu. Rev. Biochem*, 2010, 79, 413-444. Figure 1 Any one of the amino acids numbered 1-71 in the Chinese language.
[0164] In some embodiments, one or more tags or chains are linked to nanopores via cysteine bonds, one or more cysteine residues can be introduced into one or more monomers that form nanopores by substitution. In some embodiments, the nanopores can be chemically modified by linking to: (i) maleimides, including dibromomaleimides such as: 4-benzodiazepine, 1,N-(2-hydroxyethyl)maleimide, N-cyclohexylmaleimide, 1,3-maleimide propionic acid, 1,1-4-aminophenyl-1H-pyrrole,2,5,dione, 1,1-4-hydroxyphenyl-1H-pyrrole,2,5,dione, N-ethylmaleimide, N-methoxycarbonylmaleimide. Imide, N-tert-butylmaleimide, N-(2-aminoethyl)maleimide, 3-maleimide-propoxy, N-(4-chlorophenyl)maleimide, 1-[4-(dimethylamino)-3,5-dinitrophenyl]-1H-pyrrole-2,5-dione, N-[4-(2-benzimidazolyl)phenyl]maleimide, N-[4-(2-benzoxazolyl)phenyl]maleimide, N-(1-naphthyl)maleimide, N-(2,4-dimethyl)maleimide Phenyl)maleimide, N-(2,4-difluorophenyl)maleimide, N-(3-chloro-p-tolyl)-maleimide, 1-(2-amino-ethyl)-pyrrole-2,5-dione hydrochloride, 1-cyclopentyl-3-methyl-2,5-dihydro-1H-pyrrole-2,5-dione, 1-(3-aminopropyl)-2,5-dihydro-1H-pyrrole-2,5-dione hydrochloride, 3-methyl-1-[2-oxo-2-(piperazin-1-yl)ethyl]-2 5-Dihydro-1H-pyrrole-2,5-dione hydrochloride, 1-benzyl-2,5-dihydro-1H-pyrrole-2,5-dione, 3-methyl-1-(3,3,3-trifluoropropyl)-2,5-dihydro-1H-pyrrole-2,5-dione, 1-[4-(methylamino)cyclohexyl]-2,5-dihydro-1H-pyrrole-2,5-dione trifluoroacetic acid, SMILESO=C1C=CC(=O)N1CC=2C=CN=CC2, SMILES O=C1C=CC(=O)N1CN2CCNCC2、1-Benzyl-3-methyl-2,5-dihydro-1H-pyrrole-2,5-dione、1-(2-fluorophenyl)-3-methyl-2,5-dihydro-1H-pyrrole-2,5-dione、N-(4-phenoxyphenyl)maleimide、N-(4-nitrophenyl)maleimide、(ii)iodoacetamide, such as 3-(2-iodoacetamido)-propoxy、N-(cyclopropylmethyl)-2-iodoacetamide、2-iodo-N-(2-phenylethyl)acetamide、2-iodo-N-(2,2,2-trifluoroethyl)acetamide、N-(4-acetylphenyl)-2-iodoacetamide、N-(4-(aminosulfonyl)phenyl)-2-iodoacetamide、N-(1,3-Benzothiazol-2-yl)-2-iodoacetamide, N-(2,6-diethylphenyl)-2-iodoacetamide, N-(2-benzoyl-4-chlorophenyl)-2-iodoacetamide, (iii) bromoacetamides: such as N-(4-(acetamido)phenyl)-2-bromoacetamide, N-(2-acetylphenyl)-2-bromoacetamide, 2-bromo-n-(2-cyanophenyl)acetamide, 2-bromo-N-(3-(trifluoromethyl)phenyl)acetamide, N-(2-benzoylphenyl)-2-bromoacetamide, 2-bromo-N-(4-fluorophenyl)-3-methylbutyramide, N-benzyl-2-bromo-N-phenylpropionamide, N-(2-bromo-butyryl)-4-chloro-benzenesulfonamide, 2-bromo-N-methyl-N-phenylacetamide, 2-bromo- N-Phenylacetamide, 2-adamantane-1-yl-2-bromo-N-cyclohexylacetamide, 2-bromo-N-(2-methylphenyl)butyramide, acetyl-p-bromoaniline; (iv) disulfides, such as aldrithiol-2, aldrithiol-4, isopropyl disulfide, 1-(isobutyldithioalkyl)-2-methylpropane, dibenzyl disulfide, 4-aminophenyl disulfide, 3-(2-pyridyldithio)propionic acid, 3-(2-pyridyldithio)propionic acid hydrazide, 3-(2-pyridyldithio)propionic acid N-succinimide, am6amPDP1-βCD; and (v) thiols, such as 4-phenylthiazolyl-2-thiol, Purpald, 5,6,7,8-tetrahydro-quinazolin-2-thiol.
[0165] In some embodiments, the tag or tether can be attached to the nanopore directly or via one or more linkers. The tag or tether can be attached to the nanopore using hybrid linkers as described in WO 2010 / 086602. Alternatively, peptide linkers can be used. A peptide linker is an amino acid sequence. The length, flexibility, and hydrophilicity of the peptide linker are generally designed so that they do not interfere with the function of the monomer and the pore. Preferred flexible peptide linkers are extensions of 2 to 20, such as 4, 6, 8, 10, or 16 serine and / or glycine. More preferred flexible linkers comprise (SG)1, (SG)2, (SG)3, (SG)4, (SG)5, and (SG)8, where S is serine and G is glycine. Preferred rigid linkers are extensions of 2 to 30, such as 4, 6, 8, 16, or 24 proline. More preferred rigid linkers include (P) 12 , where P is proline.
[0166] spacer
[0167] In some embodiments of the methods provided herein, the analyte to be detected is a polynucleotide (“target polynucleotide”). In some embodiments, the polynucleotide or adaptor as described herein may contain spacers. For example, one or more spacers may be present in the polynucleotide adaptor. For example, the polynucleotide adaptor may contain one to about 10 adaptors, such as one to about five spacers, such as one, two, three, four, or five spacers. Spacers may include any suitable number of spacer units. Spacers provide an energy barrier that impedes the movement of dynein. For example, spacers can impede dynein by reducing the traction force of dynein on the polynucleotide. This can be achieved, for example, by using a base-free spacer, i.e., a spacer in which one or more nucleotides from the polynucleotide adaptor have been removed. Spacers can physically block the movement of dynein, for example by introducing a large chemical group to physically impede the movement of dynein.
[0168] In some embodiments, one or more spacers are included in a polynucleotide or adaptor used in the method claimed herein, in order to provide a unique signal as the polynucleotide or conjugate or adaptor passes through or across the nanopore, i.e., as the polynucleotide or conjugate or adaptor moves relative to the nanopore.
[0169] In some embodiments, the spacer may comprise a linear molecule, such as a polymer. Typically, such spacers have a structure different from the target polynucleotide. For example, if the target polynucleotide is DNA, the spacer, or each spacer, typically does not contain DNA. Specifically, if the target polynucleotide is deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), the spacer preferably comprises peptide nucleic acid (PNA), glycerol nucleic acid (GNA), threonine nucleic acid (TNA), locked nucleic acid (LNA), or a synthetic polymer with nucleotide side chains. In some embodiments, the spacer region may comprise one or more nitroindole, one or more inosine, one or more acridine, one or more 2-aminopurine, one or more 2-6-diaminopurine, one or more 5-bromo-deoxyuridine, one or more reverse thymidine (reverse dT), one or more reverse dideoxythymidine (ddT), one or more dideoxycytidine (ddC), one or more 5-methylcytidine, one or more 5-hydroxymethylcytidine, one or more 2'-O-methylRNA bases, one or more isodeoxycytidine (iso -dC), one or more isodeoxyguanosine (Iso-dG), one or more C3 (OC3H6OPO3) groups, one or more photodegradable (PC) [OC3H6-C(O)NHCH2-C6H3NO2-CH(CH3)OPO3] groups, one or more hexanediol groups, one or more spacer 9 (iSp9) [(OCH2CH2)3OPO3] groups, one or more spacer 18 (iSp18) [(OCH2CH2)6OPO3] groups; or one or more thiol groups. The spacer may include any combination of these groups. Many of these groups can be derived from... (Integrated DNA Commercially available. For example, C3, iSp9, and iSp18 spacers can all be obtained from... Obtained. Spacers may include any number of the above-mentioned groups as spacer units.
[0170] In some embodiments, the spacer may contain one or more chemical groups that cause dynein stagnation. In some embodiments, suitable chemical groups are one or more chemical side groups. One or more chemical groups may be attached to one or more nucleobases in a polynucleotide. One or more chemical groups may be attached to the backbone of a polynucleotide adaptor. Any number of suitable chemical groups may be present, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more. Suitable groups include, but are not limited to, fluorophores, streptavidin and / or biotin, cholesterol, methylene blue, dinitrophenol (DNP), digoxigenin and / or anti-digoxigenin and diphenylcyclooctynyl groups. In some embodiments, the spacer may comprise a polymer. In some embodiments, the spacer may comprise a polymer, said polymer being a polypeptide or polyethylene glycol (PEG).
[0171] The spacer may comprise one or more abasic nucleotides (i.e., nucleotides lacking a nucleotide), such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more abasic nucleotides. In the abasic nucleotides, the nucleotide may be replaced by -H (idSp) or -OH. The abasic spacer can be inserted into the target polynucleotide by removing a nucleotide from one or more adjacent nucleotides. For example, the polynucleotide may be modified to contain 3-methyladenine, 7-methylguanine, 1,N6-vinylidene adenine inosine, or hypoxanthine, and the nucleotide may be removed from these nucleotides using human alkyladenine DNA glycosidase (hAAG). Alternatively, the polynucleotide may be modified to contain uracil, and the nucleotide may be removed using uracil-DNA glycosidase (UDG). In one embodiment, the one or more spacers do not contain any abasic nucleotides.
[0172] anchor
[0173] In one embodiment, the analyte is a polynucleotide, and the analyte polynucleotide or the adaptor linked thereto includes a membrane anchor or transmembrane pore anchor, for example, linked to the adaptor. In one embodiment, the anchor facilitates the characterization of the target polynucleotide according to the methods disclosed herein. For example, the membrane anchor or transmembrane pore anchor can facilitate the localization of the selected polynucleotide around the nanopore.
[0174] Anchors can be peptide anchors and / or hydrophobic anchors that can be inserted into the membrane. In one embodiment, the hydrophobic anchor is a lipid, fatty acid, sterol, carbon nanotube, peptide, protein, or amino acid, such as cholesterol, palmitate, or tocopherol. Anchors may include thiols, biotin, or surfactants. On the one hand, anchors can be biotin (for binding to streptavidin), amylose (for binding to maltose-binding proteins or fusion proteins), Ni-NTA (for binding to polyhistidine or polyhistidine-labeled proteins), or peptides (such as antigens).
[0175] In one embodiment, the anchor may include a linker, or two, three, four, or more linkers. Preferred linkers comprise, but are not limited to, polymers such as polynucleotides, polyethylene glycol (PEG), polysaccharides, and polypeptides. These linkers may be linear, branched, or cyclic. For example, the linker may be a cyclic polynucleotide. The linker may hybridize to a complementary sequence on the cyclic polynucleotide linker. One or more anchors or one or more linkers may include components that can be cleaved or broken down, such as restriction sites or photostable groups. The linker may be functionalized with a maleimide group to link to cysteine residues in a protein. Suitable linkers are described in WO 2010 / 086602.
[0176] In one embodiment, the anchor is a cholesterol or fatty acyl chain. For example, any fatty acyl chain having a length of 6 to 30 carbon atoms, such as hexadecanoic acid, can be used. Examples of suitable anchors and methods for connecting anchors to connectors are disclosed in WO 2012 / 164270 and WO 2015 / 150786.
[0177] Controlling the movement of the analyte relative to the nanopore
[0178] The method provided herein includes one or more measurements of light scattered by light-scattering components near the nanopore as the analyte detected in the method moves relative to the nanopore.
[0179] The movement of an analyte relative to a nanopore can be driven by any suitable means. In some embodiments, the movement of the analyte relative to the nanopore is driven by physical or chemical forces (potentials). In some embodiments, the physical force is provided by an electric potential (e.g., voltage potential) or a temperature gradient, etc.
[0180] In some implementations, analytes move relative to the nanopore when a potential is applied across the nanopore. For example, polynucleotides are exemplary negatively charged analytes, so applying a potential across the nanopore will cause the polynucleotide to move relative to the nanopore under the influence of the applied potential. For instance, if a positive voltage potential is applied relative to the cis side of the nanopore to the trans side, this will induce the negatively charged analyte to move from the cis side to the trans side. Similarly, if a positive voltage potential is applied relative to the cis side of the nanopore to the trans side, this will prevent the negatively charged analyte from moving from the trans side to the cis side. The opposite occurs if a negative voltage potential is applied relative to the cis side of the nanopore to the trans side. Apparatus and methods for applying appropriate voltages are described in more detail herein.
[0181] In some implementations, the chemical force is provided by a concentration (e.g., pH) gradient.
[0182] In some embodiments, the movement of the analyte is driven by an analyte-processing enzyme. For example, in embodiments where the analyte is a biopolymer such as a polynucleotide or peptide, the movement of the polymer can be controlled by a polynucleotide-processing enzyme or a peptide-processing enzyme.
[0183] Suitable polynucleotide processing enzymes, also known as dyneins, are known in the art. Therefore, in some embodiments, the provided method includes contacting the analyte with a dynein, wherein the dynein controls the movement of the analyte relative to the nanopore.
[0184] For example, when the analyte is a polynucleotide, dynein can be present on the polynucleotide before it comes into contact with the nanopore. Alternatively, dynein can be present on an adaptor containing a portion of the polynucleotide analyte, or it can be present on a portion of the polynucleotide itself.
[0185] In some embodiments, dynamin is modified to prevent it from detaching from the polynucleotide or adaptor (rather than by impersonating the end of the polynucleotide / adaptor). Dynamin can be modified in any suitable manner. For example, dynamin can be loaded onto an adaptor or polynucleotide and then modified to prevent its detachment. Alternatively, dynamin can be modified to prevent its detachment before being loaded onto the adaptor or polynucleotide. Modification of dynamin to prevent its detachment from the polynucleotide or adaptor can be achieved using methods known in the art, such as those discussed in WO 2014 / 013260 (hereinherited in its entirety by reference), and with particular reference to the paragraph describing the modification of dynamin (a polynucleotide-binding protein) (such as a helicase) to prevent its detachment from the polynucleotide chain.
[0186] For example, dyneins may have polynucleotide unwinding openings; for example, cavities, crevices, or gaps through which the polynucleotide chain can pass when the dynein is detached from the chain. In some embodiments, the polynucleotide unwinding opening for a given dynein (polynucleotide-binding protein) can be determined by referring to its structure, such as its X-ray crystal structure. The X-ray crystal structure can be obtained in the presence and / or absence of a polynucleotide substrate. In some embodiments, the location of the polynucleotide unwinding opening in a given dynein can be inferred or confirmed by molecular modeling using standard packages known in the art. In some embodiments, the polynucleotide unwinding opening can be transiently generated by the movement of one or more portions of the dynein, such as one or more domains.
[0187] Dynamin can be modified by closing the polynucleotide helical opening. Therefore, closing the polynucleotide helical opening prevents the dynamin from dissociating from the polynucleotide or adaptor. For example, the dynamin can be modified by covalently closing the polynucleotide helical opening. In some embodiments, as described herein, the dynamin used for addressing in this manner is a helicase.
[0188] In one embodiment, the dynamin is or is derived from a polynucleotide processing enzyme. A polynucleotide processing enzyme is a polypeptide capable of interacting with and modifying at least one property of a polynucleotide. The enzyme can modify a polynucleotide by cleaving it to form individual nucleotides or shorter nucleotide chains such as dinucleotides or trinucleotides. The enzyme can also modify a polynucleotide by orienting or moving it to a specific location.
[0189] In one implementation, the dynein is derived from members of any enzyme classification (EC) group: 3.1.11, 3.1.13, 3.1.14, 3.1.15, 3.1.16, 3.1.21, 3.1.22, 3.1.25, 3.1.26, 3.1.27, 3.1.30, and 3.1.31.
[0190] In some of the claimed embodiments, the dynein is a helicase, polymerase, exonuclease, topoisomerase, folding enzyme, or a variant thereof.
[0191] In one embodiment, the dynamin is an exonuclease. Suitable enzymes include, but are not limited to, exonuclease I (SEQ ID NO:1) from *Escherichia coli*, exonuclease III (SEQ ID NO:2) from *Escherichia coli*, RecJ (SEQ ID NO:3) from *T. thermophilus*, bacteriophage λ exonuclease (SEQ ID NO:4), TatD exonuclease, and variants thereof. The three subunits, including the sequence shown in SEQ ID NO:3, or variants thereof, interact to form a trimer exonuclease.
[0192] In one implementation, the dynamin is a polymerase. The polymerase can be... 3173 DNA polymerase (which is commercially available) (Company), SD polymerase (commercially available) The enzyme is Klenow from NEB or a variant thereof. In one embodiment, the enzyme is Phi29 DNA polymerase (SEQ ID NO:5) or a variant thereof. Modified forms of the Phi29 polymerase that can be used in this invention are disclosed in U.S. Patent No. 5,576,204.
[0193] In one embodiment, the dynamite is a topoisomerase. In one embodiment, the topoisomerase is a member of either group 5.99.1.2 or 5.99.1.3 of the partial classification (EC). The topoisomerase can be a reverse transcriptase, which is an enzyme capable of catalyzing the formation of cDNA from an RNA template. These can be derived from, for example, New England... and Acquired through commercial purchase.
[0194] In one embodiment, the dynamin is a helicase. Any suitable helicase can be used according to the methods provided herein. For example, the dynamin used according to this disclosure, or each dynamin, can be independently selected from Hel308 helicase, RecD helicase, TraI helicase, TrwC helicase, XPD helicase, and Dda helicase, or variants thereof. Monomeric helicases can include several domains linked together. For example, TraI helicase and TraI subgroup helicases can contain two RecD helicase domains, a release enzyme domain, and a C-terminal domain. These domains typically form a monomeric helicase capable of functioning without forming oligomers. Specific examples of suitable helicases include Hel308, NS3, Dda, UvrD, Rep, PcrA, Pif1, and TraI. These helicases typically act on single-stranded DNA. Examples of helicases that can move along both strands of double-stranded DNA include FtfK and hexamethylenetetramer complexes, or multi-subunit complexes such as RecBCD.
[0195] Hel308 helicase is described in publications such as WO 2013 / 057495, the entire contents of which are incorporated herein by reference. RecD helicase is described in publications such as WO 2013 / 098562, the entire contents of which are incorporated herein by reference. XPD helicase is described in publications such as WO 2013 / 098561, the entire contents of which are incorporated herein by reference. Dda helicase is described in publications such as WO 2015 / 055981 and WO 2016 / 055777, the entire contents of which are incorporated herein by reference.
[0196] In one embodiment, the helicase comprises the sequence shown in SEQ ID NO:6 (Trwc Cba) or a variant thereof, the sequence shown in SEQ ID NO:7 (Hel308 Mbu) or a variant thereof, or the sequence shown in SEQ ID NO:8 (Dda) or a variant thereof. The variants may differ from the natural sequence in any of the ways discussed herein. An example variant of SEQ ID NO:8 includes E94C / A360C. Another example variant of SEQ ID NO:8 comprises E94C / A360C followed by (ΔM1)G1G2 (i.e., the deletion of M1 followed by the addition of G1 and G2).
[0197] In some embodiments, dyneins (e.g., helicases) can operate in at least two modes of activity (when the dynein has all the necessary components to promote movement, such as fuels and cofactors discussed herein, such as ATP and Mg). 2+ It controls the movement of polynucleotides in an inactive mode of operation (when dynein does not have the necessary components to promote movement).
[0198] When all the necessary components are provided to facilitate movement (i.e., in active mode), dynein (e.g., helicase) moves along the polynucleotide in a 5' to 3' or 3' to 5' direction (depending on the dynein). In embodiments where dynein is used to control the movement of the polynucleotide chain relative to the nanopore, the dynein can be used to move the polynucleotide away from (e.g., out of) the pore (e.g., against an applied force) or to move the polynucleotide toward (e.g., into) the pore (e.g., with an applied force). For example, when the dynein is captured in the pore at the end of the polynucleotide it is moving toward, the dynein works against the direction of the force and pulls the polynucleotide through out of the pore (e.g., into the cis chamber). However, when the dynein is captured in the pore from its moved-away end, the dynein works in the direction of the force and pushes the polynucleotide through into the pore (e.g., into the trans chamber).
[0199] When a dynein (e.g., a helicase) does not provide the necessary components to facilitate movement (i.e., it is in an inactive mode), it can bind to a polynucleotide and act as a brake, slowing the movement of the polynucleotide relative to the nanopore, for example, by being pulled into the pore by force. In the inactive mode, it is not important which end of the polynucleotide is captured; the applied force determines the movement of the polynucleotide relative to the pore, and the polynucleotide-binding protein acts as a brake. The control of polynucleotide movement by polynucleotide-binding proteins in the inactive mode can be described in several ways, including ratcheting, sliding, and braking.
[0200] Dynamins typically require fuel to process polynucleotides. This fuel is usually a free nucleotide or a free nucleotide analogue. Free nucleotides can be, but are not limited to, adenosine monophosphate (AMP), adenosine diphosphate (ADP), adenosine triphosphate (ATP), guanosine monophosphate (GMP), guanosine diphosphate (GDP), guanosine triphosphate (GTP), thymidine monophosphate (TMP), thymidine diphosphate (TDP), thymidine triphosphate (TTP), uridine monophosphate (UMP), uridine diphosphate (UDP), uridine triphosphate (UTP), cytidine monophosphate (CMP), cytidine diphosphate (CDP), cytidine triphosphate (CTP), cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), and deoxygenated adenosine monophosphate (dAMP). Deoxyadenosine monophosphate (dAMP), deoxyadenosine diphosphate (dADP), deoxyadenosine triphosphate (dATP), deoxyguanosine monophosphate (dGMP), deoxyguanosine diphosphate (dGDP), deoxyguanosine triphosphate (dGTP), deoxythymidine monophosphate (dTMP), deoxythymidine diphosphate (dTDP), deoxythymidine triphosphate (dTTP), deoxyuridine monophosphate (dUMP), deoxyuridine diphosphate (dUDP), deoxyuridine triphosphate (dUTP), deoxycytidine monophosphate (dCMP), deoxycytidine diphosphate (dCDP), and deoxycytidine triphosphate (dCTP). Free nucleotides are typically selected from AMP, TMP, GMP, CMP, UMP, dAMP, dTMP, dGMP, or dCMP. The most common free nucleotide is adenosine triphosphate (ATP).
[0201] The cofactor of dynein is the factor that allows dynein to function. The cofactor is preferably a divalent metal cation. The preferred divalent metal cation is Mg. 2+ Mn 2+ Ca 2+ or Co 2+ The most preferred cofactor is Mg. 2+ .
[0202] Dynamic proteins suitable for controlling the movement of peptide analytes are also well known in the art. For example, unfolding enzymes or variants thereof can be used to control the movement of peptides relative to nanopores. Unfolding enzymes include AAA+ enzymes, such as the ClpX enzyme from E. coli.
[0203] Nanopores
[0204] Any suitable transmembrane nanopore can be used in the methods disclosed herein.
[0205] Transmembrane nanopores are structures that, to some extent, cross the membrane. They allow hydrated ions, driven by an applied potential, to cross the membrane or flow within it. Transmembrane nanopores typically span the entire membrane, allowing hydrated ions to flow from one side to the other. However, transmembrane nanopores do not necessarily cross the membrane. They may be closed at one end. For example, a nanopore can be a trap, gap, channel, trench, or slit in the membrane, along which hydrated ions can flow or into it.
[0206] Any transmembrane nanopore can be used in the methods provided herein. Nanopores can be biological or artificial. Suitable pores include, but are not limited to, protein pores, polynucleotide pores, and solid pores. Nanopores can be nucleic acid nanopores, such as DNA origami pores (Langecker et al., Science, 2012; 338:932-936). Suitable DNA origami pores are disclosed in WO2013 / 083983. Nanopores can also be polymer nanopores.
[0207] In one embodiment, the nanopore is a transmembrane protein pore. A transmembrane protein pore is a polypeptide or collection of polypeptides that allows hydrated ions, such as polynucleotides, to flow from one side of the membrane to the other. In the methods provided herein, transmembrane protein pores are capable of forming pores that allow hydrated ions, driven by an applied potential, to flow from one side of the membrane to the other. Transmembrane protein pores preferably allow polynucleotides to flow from one side of the membrane (e.g., a triblock copolymer membrane) to the other. Transmembrane protein pores generally allow polynucleotides to move through the pore.
[0208] In one embodiment, the nanopore is a transmembrane protein pore, which is a monomer or oligomer. The pore preferably consists of a plurality of repeating subunits, such as at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, or at least 16 subunits. The pore is preferably a hexamer, heptamer, octamer, or non-merchanmeric pore. The pore can be a homooligomer or a heterooligomer.
[0209] In one embodiment, a transmembrane protein pore comprises a barrel or channel through which ions can flow. The subunits of the pore typically surround a central axis and contribute chains to the transmembrane β-barrel or channel, or transmembrane α-helical bundle or channel.
[0210] Typically, the barrels or channels of transmembrane protein pores comprise amino acids that facilitate interaction with analytes, such as target polynucleotides (as described herein). These amino acids are preferably located near the constriction of the barrel or channel. Transmembrane protein pores typically include one or more positively charged amino acids, such as arginine, lysine, or histidine, or aromatic amino acids, such as tyrosine or tryptophan. These amino acids typically facilitate interactions between the pore and nucleotides, polynucleotides, or nucleic acids.
[0211] In one embodiment, the nanopore is a transmembrane protein pore derived from β-barrel pores or α-helical bundle pores. β-barrel pores comprise barrels or channels formed by β-chains. Suitable β-barrel pores include, but are not limited to, β-toxins such as α-hemolysin, anthrax toxin, and leukocidin, as well as bacterial outer membrane proteins / porins, such as Mycobacterium smegmatis porins (Msp), such as MspA, MspB, MspC, or MspD, CsgG, outer membrane porin F (OmpF), outer membrane porin G (OmpG), outer membrane phospholipase A, and Neisseria autotransporter (NalP), and other pores such as cytolysins. α-helical bundle pores comprise barrels or channels formed by α-helices. Suitable α-helical bundle pores include, but are not limited to, inner membrane proteins and α-outer membrane proteins, such as WZA and ClyA toxins.
[0212] In one embodiment, the nanopore is a transmembrane pore derived from or based on Msp, α-hemolysin (α-HL), cytolysin, CsgG, ClyA, Sp1, and the hemolysin fragaceatoxin C (FraC).
[0213] In one embodiment, the nanopores are derived from CsgG, for example, from transmembrane protein pores derived from the Escherichia coli strain K-12 substrain MC4100. Such pores are oligomeric and typically comprise 7, 8, 9, or 10 monomers derived from CsgG. The pores can be homopolymeric oligomeric pores derived from CsgG comprising the same monomers. Alternatively, the pores can be heteropolymeric oligomeric pores derived from CsgG comprising at least one monomer different from the others. Examples of suitable pores derived from CsgG are disclosed in WO 2016 / 034591.
[0214] In one embodiment, the nanopore is a transmembrane pore derived from lysozyme. Examples of suitable pores derived from lysozyme are disclosed in WO 2013 / 153359.
[0215] In one embodiment, the nanopore is derived from or based on transmembrane pore α-hemolysin (α-HL). Wild-type α-hemolysin pores are formed by seven identical monomers or subunits (i.e., they are heptameric). α-hemolysin pores can be α-hemolysin-NN or variants thereof. Variants preferably include N residues at positions E111 and K147.
[0216] In one embodiment, the nanopore is a transmembrane protein pore derived from Msp, such as MspA. Examples of suitable pores derived from MspA are disclosed in WO2012 / 107778.
[0217] In one implementation, the nanopores are transmembrane pores derived from or based on ClyA.
[0218] medium
[0219] The methods described herein involve detecting analytes in a medium containing light-scattering components. Any suitable medium can be used.
[0220] In some implementations, the medium is an aqueous or non-aqueous (e.g., organic) solvent. Ionic liquids may also be used. Aqueous solutions are preferred.
[0221] The medium is the solvent for the analyte and the light-scattering component. Therefore, the choice of medium will depend on the analyte to be detected and the light-scattering component used. Generally, an aqueous, water-based medium containing one or more buffers, electrolytes, etc., is suitable.
[0222] The method can be carried out in the presence of charge carriers, such as metal salts, for example alkali metal salts; halides, such as chloride salts like alkali metal chloride salts. Charge carriers are particularly suitable when the movement of the analyte, as described herein, is driven by a potential (e.g., voltage).
[0223] The charge carriers may comprise ionic liquids or organic salts, such as tetramethylammonium chloride, trimethylphenylammonium chloride, phenyltrimethylammonium chloride, or 1-ethyl-3-methylimidazolium chloride. Potassium chloride (KCl), sodium chloride (NaCl), or cesium chloride (CsCl) is commonly used. KCl is preferred. The salt may be an alkaline earth metal salt, such as calcium chloride (CaCl2). The salt concentration may be saturated. The salt concentration may be 3 M or lower and is typically 0.1 to 2.5 M, for example 0.3 to 1.9 M, for example 0.5 to 1.8 M, for example 0.7 to 1.7 M, for example 0.9 to 1.6 M, for example 1 M to 1.4 M. In some embodiments, lower salt concentrations are useful, for example, these can stabilize the membrane or promote the solubility of only slightly soluble light-scattering components or analytes. In some embodiments, higher salt concentrations are useful, for example, when the movement of light-scattering components and / or analytes is driven by an applied power.
[0224] Characterization methods are typically performed in the presence of a buffer solution. Any suitable buffer solution can be used. Typically, the buffer solution is HEPES. Another suitable buffer solution is Tris-HCl buffer. The methods are typically performed at the following pH values: 4.0 to 12.0, 4.5 to 10.0, 5.0 to 9.0, 5.5 to 8.8, 6.0 to 8.7, or 7.0 to 8.8, or 7.5 to 8.5. The pH value used is preferably about 7.5.
[0225] membrane
[0226] In the methods presented in this paper, transmembrane nanopores are typically present within the membrane. Any suitable membrane can be used.
[0227] The membrane is preferably an amphiphilic layer. An amphiphilic layer is a layer formed by amphiphilic molecules such as phospholipids, possessing both hydrophilic and lipophilic properties. The amphiphilic molecules can be synthetic or naturally occurring. Non-naturally occurring amphiphiles and amphiphiles forming monolayers are known in the art, and include, for example, block copolymers (Gonzalez-Perez et al., Langmuir, 2009, 25, 10447-10450). A block copolymer is a polymeric material in which two or more monomer subunits polymerized together form a single polymer chain. Block copolymers typically possess properties contributed by each monomer subunit. However, block copolymers can possess unique properties not found in polymers formed from individual subunits. Block copolymers can be engineered so that one of the monomer subunits is hydrophobic (i.e., lipophilic) in an aqueous medium, while the other subunits are hydrophilic. In this case, the block copolymer can possess amphiphilic properties and can form a structure mimicking a biological membrane. Block copolymers can be diblock (consisting of two monomer subunits), but can also be constructed from more than two monomer subunits, forming a more complex arrangement exhibiting amphiphilic behavior. The copolymer can be triblock, tetrablock, or pentablock copolymers. The membrane is preferably a triblock copolymer membrane.
[0228] Archaea bipolar tetraether lipids are naturally occurring lipids that are constructed to form monolayer membranes. These lipids are generally found in extremophiles, thermophiles, halophiles, and acidophiles that survive in harsh biological environments. Their stability is thought to stem from the fusion properties of the final bilayer. A straightforward approach is to construct block copolymer materials that mimic these biological entities by generating triblock polymers with a general motif of hydrophilic-hydrophobic-hydrophilic properties. Such materials can form monomeric membranes that exhibit characteristics similar to lipid bilayers and encompass a range of stages of behavior from vesicles to lamellar membranes. Membranes formed from these triblock copolymers retain several advantages over biological lipid membranes. Because of the synthesis of triblock copolymers, precise construction can be carefully controlled to provide the correct chain lengths and properties required for membrane formation and interaction with pores and other proteins.
[0229] Block copolymers can also be constructed from subunits not classified as lipid submaterials; for example, hydrophobic polymers can be made from siloxanes or other non-hydrocarbon-based monomers. The hydrophilic subsegments of the block copolymers can also possess low protein-binding properties, allowing for the creation of highly resistant membranes when exposed to pristine biological samples. This head unit can also be derived from non-classical lipid head units.
[0230] Compared to bio-lipid membranes, triblock copolymer membranes also exhibit increased mechanical and environmental stability, such as a much wider operating temperature or pH range. The synthetic properties of block copolymers provide a platform for customizing polymer-based membranes for a wide range of applications.
[0231] In some embodiments, the membrane is one of the membranes disclosed in International Application No. 2014 / 064443 or No. 2014 / 064444.
[0232] Amphiphilic molecules can be chemically modified or functionalized to facilitate the coupling of polynucleotides. The amphiphilic layer can be monolayer or bilayer. The amphiphilic layer is typically planar. The amphiphilic layer can be curved. The amphiphilic layer can be supportive.
[0233] Amphiphilic membranes are usually naturally mobile, essentially at about 10 -8 cm s -1 The lipid diffusion rate acts as a two-dimensional liquid. This means that pores and coupled polynucleotides can normally move within the amphiphilic membrane.
[0234] The membrane can be a lipid bilayer. Lipid bilayers are models of cell membranes and serve as excellent platforms for a range of experimental studies. For example, lipid bilayers can be used for in vivo studies of membrane proteins via single-channel recording. Alternatively, lipid bilayers can be used as biosensors to detect the presence of a range of substances. A lipid bilayer can be any lipid bilayer. Suitable lipid bilayers include, but are not limited to, planar lipid bilayers, supported bilayers, or liposomes. Preferably, a planar lipid bilayer is a flat lipid bilayer. Suitable lipid bilayers are disclosed in WO 2008 / 102121, WO 2009 / 077734, and WO 2006 / 100484.
[0235] Methods for forming lipid bilayers are known in the art. Lipid bilayers are typically formed by the method of Montal and Mueller (Proceedings of the National Academy of Sciences, 1972; 69:3561-3566), in which a lipid monolayer is carried on an aqueous / air interface across an opening perpendicular to the interface. The lipid is typically added to the surface of an aqueous electrolyte solution by first dissolving the lipid in an organic solvent and then evaporating a drop of solvent from the surface of the aqueous solution on either side of the opening. Once the organic solvent has evaporated, the solution / air interface on either side of the opening physically moves back and forth through the opening until a bilayer is formed. Planar lipid bilayers can be formed across openings in a membrane or across openings in a groove.
[0236] The Montal and Mueller method is commonly used because it is cost-effective and a relatively straightforward method for forming a good-quality lipid bilayer suitable for protein pore insertion. Other common methods for bilayer formation include tip immersion, bilayer brushing, and patch clamping.
[0237] Tip-immersion bilayer formation requires contact between the open end surface (e.g., a pipette tip) and the surface of the test solution carrying the lipid monolayer. Similarly, a lipid monolayer is first generated at the solution / air interface by evaporating a drop of lipid dissolved in an organic solvent at the solution surface. The bilayer is then formed via a Langmuir-Schaefer process, requiring mechanical automation to move the open end relative to the solution surface.
[0238] For the brush-coated bilayer, a drop of lipid dissolved in an organic solvent is applied directly to an opening immersed in an aqueous test solution. Using a brush or equivalent, the lipid solution is thinly diffused within the opening. This solvent dilution allows the formation of a lipid bilayer. However, completely removing the solvent from the bilayer is very difficult, and therefore the bilayer formed by this method is less stable and more prone to noise during electrochemical measurements.
[0239] Patch clamping is commonly used in biological cell membrane research. The cell membrane is clamped to the end of a pipette by aspiration, and the membrane patch becomes attached within an opening. This method is suitable for generating lipid bilayers by clamping and then bursting liposomes to detach from the lipid bilayer sealed within an opening of the pipette. This method requires stable, large, monolayer liposomes and the fabrication of small openings in a material with a glass surface.
[0240] Liposomes can be formed by sonication, extrusion or the Mozafari method (Colas et al. (2007) Micron 38:841-847).
[0241] In some embodiments, a lipid bilayer is formed as described in International Application WO 2009 / 077734. It is advantageous in this method to form the lipid bilayer from dried lipids. In a most preferred embodiment, the lipid bilayer is formed across an opening, as described in WO2009 / 077734.
[0242] A lipid bilayer is formed by two opposing lipid layers. The two lipid layers are arranged such that their hydrophobic tail groups face each other, forming a hydrophobic interior. The hydrophilic head groups of the lipids face outwards towards the aqueous environment on each side of the bilayer. The bilayer can exist in various lipid stages, including but not limited to liquid disordered stages (liquid sheets), liquid ordered stages, solid ordered stages (sheet-gel stages, interleaved gel stages), and planar bilayer crystals (sheet-subgel stages, sheet-crystalline stages).
[0243] Any lipid composition that forms a lipid bilayer can be used. The lipid composition is selected such that the lipid bilayer possesses desired properties, such as surface charge, ability to support membrane proteins, filling density, or the mechanical properties formed. The lipid composition may include one or more different lipids. For example, the lipid composition may contain up to 100 lipids. The lipid composition preferably contains 1 to 10 lipids. The lipid composition may include naturally occurring lipids and / or artificial lipids.
[0244] Lipids typically consist of a head group, an interfacial portion, and two hydrophobic tail groups that may be the same or different. Suitable head groups include (but are not limited to): neutral head groups, such as diacylglycerol esters (DG) and ceramides (CM); zwitterionic head groups, such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), and sphingomyelin (SM); negatively charged head groups, such as phosphatidylglycerol (PG); phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidic acid (PA), and cardiolipin (CA); and positively charged head groups, such as trimethylammonium propane (TAP). Suitable interfacial portions include, but are not limited to, naturally occurring interfacial portions, such as glycerol-based or ceramide-based portions. Suitable hydrophobic tail groups include, but are not limited to: saturated hydrocarbon chains, such as lauric acid (n-dodecanoic acid), myristic acid (n-tetradecanoic acid), palmitic acid (n-hexadecanoic acid), stearic acid (n-octadecanoic acid), and arachidic acid (n-eicosanoic acid); unsaturated hydrocarbon chains, such as oleic acid (cis-9-octadecanoic acid); and branched hydrocarbon chains, such as phytanoyl groups. The chain length and the position and number of double bonds in the unsaturated hydrocarbon chain can vary. The chain length and the position and number of branches (such as methyl groups) in the branched hydrocarbon chain can also vary. The hydrophobic tail group can be attached to the interfacial portion as an ether or ester. Lipids can be mycolic acids.
[0245] Lipids can also be chemically modified. The head or tail groups of lipids can be chemically modified. Suitable lipids with chemically modified head groups include, but are not limited to: PEG-modified lipids, such as 1,2-diacyl-sn-glycerol-3-phosphate ethanolamine-N-[methoxy(polyethylene glycol)-2000]; functionalized PEG lipids, such as 1,2-distearate-sn-glycerol-3-phosphate ethanolamine-N-[biotinyl(polyethylene glycol)2000]; and lipids for conjugation modification, such as 1,2-dioleoyl-sn-glycerol-3-phosphate ethanolamine-N-(succinyl) and 1,2-dispalmitoyl-sn-glycerol-3-phosphate ethanolamine-N-(biotinyl). Suitable lipids with chemically modified tails include, but are not limited to: polymerizable lipids, such as 1,2-bis(10,12-tetracarbadiynyl)-sn-glycerol-3-phosphate choline; fluorinated lipids, such as 1-palmitoyl-2-(16-fluoropalmitoyl)-sn-glycerol-3-phosphate choline; deuterated lipids, such as 1,2-dipalmitoyl-D62-sn-glycerol-3-phosphate choline; and ether-linked lipids, such as 1,2-di-O-phytyl-sn-glycerol-3-phosphate choline. Lipids may be chemically modified or functionalized to facilitate coupling with polynucleotides.
[0246] Amphiphilic layers, such as lipid compositions, typically include one or more additives that will affect the properties of the layer. Suitable additives include, but are not limited to: fatty acids, such as palmitic acid, myristic acid, and oleic acid; fatty alcohols, such as palmitol, myristicol, and oleyl alcohol; sterols, such as cholesterol, ergosterol, lanosterol, sitosterol, and stigmasterol; lysophospholipids, such as 1-acyl-2-hydroxy-sn-glycerol-3-phosphocholine; and ceramides.
[0247] In another embodiment, the membrane includes a solid layer. The solid layer can be formed of both organic and inorganic materials, including, but not limited to: microelectronic materials, insulating materials (such as Si3N4, Al2O3, and SiO), organic and inorganic polymers (such as polyamides), and plastics (such as...). The membrane may consist of an amphiphilic membrane or layer, such as a two-component addition-cured silicone rubber, or glass. The solid layer may be formed from graphene. Suitable graphene layers are disclosed in WO 2009 / 035647. If the membrane includes a solid layer, pores are typically present in the amphiphilic membrane or layer contained within the solid layer, for example, in pores, holes, gaps, channels, trenches, or slots within the solid layer. Suitable solid / amphiphilic hybrid systems can be prepared by those skilled in the art. Suitable systems are disclosed in WO 2009 / 020682 and WO 2012 / 005857. Any of the amphiphilic membranes or layers discussed above may be used.
[0248] In some embodiments of the method described herein, nanopores exist within the droplet interfacial bilayer (DIB).
[0249] A droplet interfacial bilayer can be formed by bringing two or more droplets into contact, each droplet containing an amphiphilic coating. The contact of the amphiphilic coatings on the droplets displaces any surrounding medium (e.g., oil in which droplets can form) and results in the formation of a bilayer between the amphiphiles. Droplet interfacial bilayers are known in the art and described, for example, in WO2014 / 064444, the entire contents of which are incorporated herein by reference. In some embodiments of the claimed method, nanopores are present in the DIB. Such embodiments include generating a flux of light-scattering components from the first droplet to the second droplet through a nanopore connecting the first and second droplets, and measuring the light scattered by the light-scattering components once or multiple times near the nanopore as the analyte moves relative to the nanopore, for example, as the analyte moves through the nanopore from the first droplet to the second droplet. The droplets can have any suitable size and can be miniaturized, for example, by having a nanoliter volume. For example, the volume of the droplets in the DIB can be from about 50 nL to about 5000 nL, for example from about 100 nL to about 1000 nL, for example from about 200 nL to about 600 nL, for example from about 250 nL to about 500 nL, for example from about 300 nL to about 400 nL, for example from about 350 nL.
[0250] In other embodiments, the DIB can be formed between a droplet and a support, such as a lipid-coated solid support. An example of a suitable support is a solid material coated with a polymer. For example, a glass substrate can be used. A suitable polymer coating is a polysaccharide coating, such as agarose. The substrate, such as a glass substrate, can be provided, for example, in the form of a "coverslip," which can be coated with the polymer coating, for example, by spin coating. The polymer coating is typically a thin layer of about 50 nm to about 500 nm, for example, about 100 nm to about 300 nm, for example, about 200 nm. A lipid-coated support can be obtained by incubating or otherwise contacting the polymer-coated substrate with a suitable lipid, such as DPhPC.
[0251] The methods disclosed herein are typically carried out using the following methods: (i) an artificial amphiphilic layer comprising a pore, (ii) a separated, naturally occurring lipid bilayer comprising a pore, or (iii) a cell into which the pore is inserted. Artificial amphiphilic layers (such as artificial triblock copolymer layers) are typically used to perform the methods. These layers may include other transmembrane and / or intramembrane proteins and other molecules besides the pore. Suitable apparatus and conditions are discussed below. The methods provided herein are typically performed in vitro.
[0252] In some embodiments of the methods provided herein, nanopores exist in an array of multiple nanopores. The nanopores can exist in a droplet interfacial bilayer array; for example, an array of droplets can be formed. Each droplet can contain one or more nanopores within the array of each droplet.
[0253] Nanopore arrays can be generated in silicon-based pore arrays. For example, in some embodiments, each array contains 128, 256, 512, 1024, 2000, 3000, 4000, 6000, 10000, 12000, 15000 or more pores.
[0254] Determinable measurements and characteristics
[0255] In one implementation, the presence, absence, or one or more properties of a target analyte is determined. The method can be used to determine the presence, absence, or one or more properties of at least one target analyte. The method can involve determining the presence, absence, or one or more properties of two or more target analytes. The method can include determining the presence, absence, or one or more properties of any number of target analytes (e.g., 2, 5, 10, 15, 20, 30, 40, 50, 100, or more target polynucleotides). Any number of properties of one or more target analytes can be determined, such as 1, 2, 3, 4, 5, 10, or more properties.
[0256] Therefore, this document also provides a method for characterizing an analyte, comprising performing the method described herein; and performing one or more measurements as the analyte moves relative to the nanopore, wherein the one or more measurements indicate one or more properties of the analyte, and thereby characterizing the analyte as it moves relative to the nanopore.
[0257] More specifically, this paper provides a method for characterizing analytes, wherein the analytes are present in a medium containing light-scattering components, the method comprising:
[0258] - To bring the medium into contact with the nanopores;
[0259] - Generates the flux of the component through the nanopores;
[0260] - Contact the analyte with the nanopore, such that the analyte affects the flux of the component through the nanopore;
[0261] - Irradiate the medium near the nanopore with one or more light sources; and
[0262] - As the analyte moves relative to the nanopore, one or more measurements are taken of the light scattered by the components near the nanopore, wherein the one or more measurements indicate one or more properties of the analyte, thereby characterizing the analyte as it moves relative to the nanopore.
[0263] In such methods, the analytes, media, light-scattering components, nanopores, light sources, and measurements performed are typically described in more detail herein.
[0264] As described above, the analyte is typically a polynucleotide or peptide, particularly a polynucleotide. When the analyte is a polynucleotide or polypeptide, a preferred characteristic that can be identified is the sequence of the polynucleotide or polypeptide. Other characteristics that can be identified include whether the polynucleotide or polypeptide is modified and the extent and / or amount of any such modification that may be present; the identity of the polynucleotide or polypeptide; and the secondary structure of the polynucleotide or polypeptide. Modifications that can be characterized in the methods of the present invention include whether the polynucleotide or polypeptide is modified and to what extent (e.g., by methylation, by oxidation, by damage, with one or more proteins or with one or more labels, tags, or spacers).
[0265] In view of the above discussion, it is clear that in some embodiments, this document provides a method for detecting polynucleotide or peptide analytes in an aqueous medium containing a hydrophilic, water-soluble, light-scattering component, the method comprising:
[0266] - To bring the medium into contact with the transmembrane protein nanopores;
[0267] - By applying an electric potential and / or a concentration gradient of the light-scattering component across the nanopore, a flux of the component through the nanopore is generated;
[0268] - Contact the analyte with the nanopore, such that the analyte affects the flux of the component through the nanopore;
[0269] - Irradiate the medium near the nanopore with one or more light sources; and
[0270] - As the analyte moves relative to the nanopore, the light scattered by the components near the nanopore is measured once or multiple times, thereby detecting the analyte as it moves relative to the nanopore;
[0271] The measurement of light scattered by the components, either once or multiple times, includes detecting the interference between the scattered signal and the reference beam.
[0272] In some other embodiments, this document provides a method for detecting polynucleotide analytes in an aqueous medium containing sugars or polymeric light-scattering components (e.g., sucrose or polyethylene glycol), the method comprising:
[0273] - To bring the medium into contact with the transmembrane β-barrel protein nanopores;
[0274] - By providing a concentration gradient of the light-scattering components across the nanopores, a flux of components through the nanopores is generated;
[0275] - Contact the analyte with the nanopore, such that the analyte affects the flux of the component through the nanopore;
[0276] - Irradiating the medium near the nanopore with one or more light sources, wherein the one or more light sources optionally include at least one laser; and
[0277] - As the analyte moves relative to the nanopore, one or more iSCAT measurements are performed on the light scattered by the components near the nanopore, thereby detecting the analyte as it moves relative to the nanopore;
[0278] One or more measurements of the light scattered by the components include detecting the interference between the scattered signal and a reference beam provided by the reflected beam from the interface;
[0279] Optionally, the nanopores exist in the droplet interface bilayer.
[0280] equipment
[0281] An apparatus for implementing the methods provided herein is also provided. Therefore, in one embodiment, an apparatus is provided comprising:
[0282] - A chamber having a volume containing a medium comprising light-scattering components;
[0283] - A membrane containing nanopores, wherein the nanopores are in contact with the medium;
[0284] - One or more light sources are used to irradiate the volume near the nanopores; and
[0285] - A detector used to detect light scattered by the component.
[0286] In some embodiments, the detector is configured to detect interference between a scattered signal corresponding to the flux of the component through the nanopore and a reference beam. The detector can be any detector described herein.
[0287] In some implementations, the medium contains an analyte for detection using the device. The medium and analyte are typically described in more detail herein.
[0288] The device may also include a dynamite for controlling the movement of the analyte relative to the nanopore. The dynamite can be any dynamite described herein, for example.
[0289] The device can be a microfluidic device. Therefore, the device can be miniaturized. In some embodiments, the minimum detection device may include a single LED, a photodiode, and the generated scattering signal may correspond to the flux of a light-scattering component, such as sucrose, through a single nanopore, which, for example as described herein, is located in a droplet interface bilayer between two nanoliter-volume droplets or between a nanoliter-volume droplet and a solid support. The device may include an additional reference beam.
[0290] More specifically, the device may include a chamber containing an aqueous solution and a barrier dividing the chamber into two sections. The barrier typically has openings in which a membrane containing transmembrane nanopores is formed. Transmembrane pores are described herein.
[0291] In other embodiments, the device may include a chamber comprising a plurality of droplets connected by one or more droplet interface bilayers. Nanopores may be present in at least one droplet interface bilayer to connect the droplets. As described in WO 2009 / 024775, the droplets may be supported by a hydrogel layer.
[0292] Although this method does not rely on the electrical detection of ion current, the features of the devices described in WO 2008 / 102120, WO 2010 / 122293 or WO 00 / 28312 may be useful.
[0293] The methods described herein may include applying an electrical (e.g., potential) gradient across the nanopore, for example, to drive the flux of light-scattering components and / or analytes to be detected. Therefore, the device may also include circuitry capable of applying a potential and optionally measuring electrical signals across the membrane and pore. The potential can be applied using patch clamps or voltage clamps.
[0294] The device can apply voltage across the membrane and pores. The voltage used is typically +2V to -2V, and typically -400mV to +400mV. The voltage used is preferably within a range having a lower limit selected from -400mV, -300mV, -200mV, -150mV, -100mV, -50mV, -20mV, and 0mV, and the upper limit is independently selected from +10mV, +20mV, +50mV, +100mV, +150mV, +200mV, +300mV, and +400mV. The voltage used is more preferably within the range of 100mV to 240mV, and most preferably within the range of 120mV to 220mV. If the voltage is used to drive the movement of the analyte relative to the nanopore, in some embodiments, resolution (e.g., increasing the distinction between different nucleotides in a polynucleotide analyte) can be improved by using an increased applied potential.
[0295] Characterization methods can be performed at the following temperatures: 0°C to 100°C, 15°C to 95°C, 16°C to 90°C, 17°C to 85°C, 18°C to 80°C, 19°C to 70°C, or 20°C to 60°C. Characterization is typically performed at room temperature. Optionally, characterization can be performed at temperatures that support enzyme function, such as approximately 37°C.
[0296] The device may include silicon-based arrays of holes, wherein each array comprises 128, 256, 512, 1024, 2000, 3000, 4000, 6000, 10000, 12000, 15000 or more holes.
[0297] system
[0298] A system for implementing the methods provided herein is also provided. Therefore, in one embodiment, the present document provides a system comprising:
[0299] - A medium containing light-scattering components;
[0300] - Nanopores in contact with the medium;
[0301] - The medium near the nanopore is illuminated by one or more light sources; and
[0302] - Reference light source.
[0303] In another embodiment, a system is provided, comprising:
[0304] - A medium containing light-scattering components;
[0305] - Nanopores in contact with the medium;
[0306] - The medium near the nanopore is illuminated by one or more light sources; and
[0307] - A detector used to detect light scattered by light-scattering components near the nanopores.
[0308] In another embodiment, a system is provided, comprising:
[0309] - A medium containing light-scattering components selected from carbohydrates, amino acids, polymers, and electrolytes;
[0310] - Nanopores in contact with the medium; and
[0311] The medium near the nanopore is irradiated by one or more light sources.
[0312] In another embodiment, a system is provided, comprising:
[0313] - A medium containing light-scattering components;
[0314] - Nanopores in contact with the medium;
[0315] - The medium near the nanopore is illuminated by one or more light sources; and
[0316] - Dynamic proteins used to control the movement of analytes relative to nanopores.
[0317] Typically, in such systems, the light-scattering component is non-fluorescent. In some embodiments, the system includes the flux of said component through said nanopores. Typically, the component is a hydrophilic, uncharged molecule, such as hydrocarbons, solvents, organic molecules such as carbohydrates, amino acids (including oligopeptides and polypeptides), sugars (including oligosaccharides and polysaccharides), nucleic acids (e.g., polynucleotides), non-biological polymers, salts and other electrolytes, amphiphiles, and surfactants. The light-scattering component typically does not contain a fluorophore.
[0318] In some implementations, the system also includes an analyte for detection using the system. For example, the analyte can be any analyte as described in more detail herein.
[0319] In some embodiments, the system may further include additional components, such as detectors for detecting light scattered by components near the nanopores and / or kinetic proteins for controlling the motion of the analyte relative to the nanopores. The detectors and / or kinetic proteins may be described in more detail herein.
[0320] In systems requiring protection, the analyte, medium, light-scattering components, nanopores, light source, reference light source, and measurements performed are typically described in more detail herein.
[0321] It should be understood that while specific embodiments, constructions, and materials and / or molecules have been discussed herein with respect to the method according to the invention, various changes or modifications in form and detail may be made without departing from the scope and spirit of the invention. The following examples are provided to better illustrate specific embodiments and should not be construed as limiting the scope of this application. This application is limited only by the claims.
[0322] Example
[0323] Example 1
[0324] This embodiment describes devices and systems that can be used to perform the claimed methods.
[0325] Droplet interface bilayers (DIBs) were generated according to the schemes described in the following literature: Wit, G.de, Danial, JSH, Kukura, P. & Wallace, MI, “Dynamic label-free imaging of lipid nanodomains.” Proceedings of the National Academy of Sciences, USA, 112, 12299–12303 (2015); and Leptihn S., Castell OK, Cronin B., Lee EH, Gross LCM, Marshall DP, Thompson JR, Holden M., & Wallace MI, “Constructing Droplet Interface Bilayers from the Contact of Aqueous Droplets in Oil”. Nature Protocols (2013) 8, 1048.
[0326] Staphylococcus aureus α-hemolysin (αHL) WT heptamer protein was expressed and purified in Escherichia coli according to a standard protocol.
[0327] 1.2 nM αHL and the analyte (described below) were placed in a 200–350 nL droplet (1.32 M KCl, 8.8 mM HEPES, pH 7.0) and incubated in 3 mM 1,2-diphytyl-sn-glycero-3-phosphocholine (DPhPC) in hexadecane to form a lipid monolayer. The droplet was then transferred to a coverslip in a microfabricated PMMA (polymethyl methacrylate) device by pipetting. Figure 1 ).
[0328] A thin layer (~200 nm) of agarose (0.8 M KCl, 1 M sucrose, 8.8 mM HEPES, pH 7.0) was spin-coated (3,000 rpm, 30 s) onto a coverslip and then incubated with 3 mM DPhPC in hexadecane. Upon contact with the monolayer on the agarose, the lipid-coated droplets spontaneously formed a diabetic bin (DIB).
[0329] It was found that the potential applied by electrodes inserted into the agarose layer and droplet (e.g., 80 mV) was suitable for controlling the flux through the αHL pore. Alternatively, the osmotic gradient could be used to indirectly control the flux. Here, KCl was omitted from the droplet, and no electrodes were inserted.
[0330] The DIB and apparatus are placed on an interference microscope, which features AOD (acoustic-optical deflector) assisted laser illumination and CMOS detection, as described in the following literature: HLE Coker, MRR Cheetham, DR Kattnig, YJ Wang, S. Garcia-Manyes, & M.I. Wallace, “Controlling Anomalous Diffusion in Lipid Membranes”, arXiv:1709.04698; accessible at https: / / arxiv.org / pdf / 1709.04698.pdf. A schematic diagram of the interference microscope setup is shown below. Figure 2 As shown.
[0331] A liquid flux with a refractive index different from the surrounding environment flows from the agarose layer into the droplets, providing a scattering source that differs from the surrounding medium. The interference between this scattered light, provided by reflection from the glass cover glass, and the reference beam generates a signal detectable using a CMOS camera. Figure 3 ).
[0332] A stable diffusion signal was detected in the presence of aHL nanopores using a 1M sucrose gradient in the absence of analyte. Results are as follows: Figure 4 As shown (20 ms per frame, montage of diffuse aHL; images processed by dividing by the median image). No signal was detected in the absence of sucrose.
[0333] DIBs with refractive index gradients exhibit point-like diffraction-limited diffusion sites with voltage-dependent flux. Results obtained at 80 mV are shown in Figure 5. Figure 5A Multiple nanopores. Figure 5B In poly-C 40 Time series (50 ms / fr) from a single nanopore in the presence of DNA. Intensity variations depend on the applied potential and the aHL nanopore and poly-C 40 The presence of DNA analytes demonstrates the ability of the method presented in this paper to detect the movement of DNA relative to nanopores.
[0334] When a square wave potential (+ / -80mV) is applied, a corresponding switch in the optical signal from a single aperture is detected. Figure 6 (Each slice corresponds independently to a 20ms frame; each slice displays the recorded data for a single hole).
[0335] Example 2
[0336] This embodiment further illustrates the detection of interference signals at a single α-hemolysin nanopore site diffused in a droplet interface bilayer.
[0337] The droplet interface bilayer (DIB) is generated according to the scheme described in Leptihn S., Castell OK, Cronin B., Lee EH, Gross LCM, Marshall D.P., Thompson JR, Holden M., & Wallace MI, “Constructing Droplet Interface Bilayers from the Contact of Aqueous Droplets in Oil”, Nature Protocols (2013) 8, 1048.
[0338] Staphylococcus aureus α-hemolysin (αHL) WT heptamer protein was expressed and purified in Escherichia coli according to a standard protocol.
[0339] 22 nM αHL was placed in a droplet containing 300 mM KCl, 20 mM HEPES (pH 7.0), and 2 M sucrose, and then in a solution containing 2 x 10⁻⁶ hexadecane. -8 mol% cap biotin-DHPE (N-(Biotin)-1,2-bis(hexadecanoyl-sn-glycero-3-phosphoethanolamine)C16:Ar-20 [9:1] was incubated in 9.5 mg / mL DPhPC to form a lipid monolayer. The droplets were transferred to plasma-cleaned coverslips by pipetting.
[0340] A thin layer of agarose (substrate agarose: 0.5 wt% ultra-low melting point agarose; product code: A5030, Sigma Aldrich; rehydrated agarose: 1.2 wt% agarose, product code: A9414, Sigma Aldrich; 300 mM KCl, 2.44 M glucose, 20 mM HEPES, pH 7.0) was spin-coated (3,000 rpm, 30 s) onto a coverslip and then incubated with a lipid mixture in hexadecane. Upon contact with the monolayer on the agarose, the lipid-coated droplets spontaneously formed a diabetic bin (DIB).
[0341] As described in Example 1, the DIB and the device were placed on an interference microscope. A potential was applied through electrodes inserted into the agarose layer. Interference scattering caused by the flux through a single αHL nanopore in response to the applied potential was detected using the following imaging conditions:
[0342] Imaging conditions: Irradiation at 700mW at 650nm. Images were captured at 150FPS using a CMOS camera.
[0343] Image processing: Subtract median Z stack. Minimum / maximum pixels displayed: 0.96-1.03 contrast.
[0344] Z-projection: The average contrast of the circular area drawn around each point.
[0345] The result is Figure 7 The contrast changes corresponding to interference scattering caused by the flux of sucrose through the pores were recorded in response to an applied square wave potential (+ / -200 mV). The contrast signal responded rapidly and reproducibly to the applied potential. Each trace corresponds to a different nanopore.
[0346] Sequence List Description
[0347] SEQ ID NO:1 shows the amino acid sequence of (hexahistidine-labeled) exonuclease I (EcoExo I) from Escherichia coli.
[0348] SEQ ID NO:2 shows the amino acid sequence of exonuclease III from Escherichia coli.
[0349] SEQ ID NO:3 shows the amino acid sequence of the RecJ enzyme (TthRecJ-cd) from thermophilic bacteria.
[0350] SEQ ID NO:4 shows the amino acid sequence of the bacteriophage λ exonuclease. This sequence is one of the three identical subunits that assemble into the trimer.
[0351] (http: / / www.neb.com / nebecomm / products / productM0262.asp).
[0352] SEQ ID NO:5 shows the amino acid sequence of Phi29 DNA polymerase from Bacillus subtilis.
[0353] SEQ ID NO:6 shows the amino acid sequence of the Trwc Cba (Citromicrobium bathyomarinum) helicase.
[0354] SEQ ID NO:7 shows the amino acid sequence of the helicase from Hel308 Mbu (Methanococcoides burtonii).
[0355] SEQ ID NO:8 shows the amino acid sequence of Dda helicase 1993 from Enterobacter T4 bacteriophage.
[0356] sequence list
[0357] SEQ ID NO:1 - Exonuclease I from Escherichia coli
[0358] MMNDGKQQSTFLFHDYETFGTHPALDRPAQFAAIRTDSEFNVIGEPEVFYCKPADDYLPQPGAVLITGITPQEARAKGENEAAFAARIHSLFTVPKTCILGYNNVRFDDEVTRNIFYRNFYDPYAWSWQHDNSRWDLLDVMRACYALRPEGINWPENDDGLPSFRLEHLTKANGIEHSNAHDAMADVYATIAMAKLVKTRQPRLFDYLFTHRNKHKLMALIDVPQMKPLVHVSGMFGAWRGNTSWVAPLAWHPENRNAVIMVDLAGDISPLLELDSDTLRERLYTAKTDLGDNAAVPVKLVHINKCPVLAQANTLRPEDADRLGINRQHCLDNLKILRENPQVREKVVAIFAEAEPFTPSDNVDAQLYNGFFSDADRAAMKIVLETEPRNLPALDITFVDKRIEKLLFNYRARNFPGTLDYAEQQRWLEHRRQVFTPEFLQGYADELQMLVQQYADDKEKVALLKALWQYAEEIVSGSGHHHHHH
[0359] SEQ ID NO: 2 - Exonuclease III enzyme from Escherichia coli
[0360] MKFVSFNINGLRARPHQLEAIVEKHQPDVIGLQETKVHDDMFPLEEVAKLGYNVFYHGQKGHYGVALLTKETPIAVRRGFPGDDEEAQRRIIMAEIPSLLGNVTVINGYFPQGESRDHPIKFPAKAQFYQNLQNYLETELKRDNPVLIMGDMNISPTDLDIGIGEENRKRWLRTGKCSFLPEEREWMDRLMSWGLVDTFRHANPQTADRFSWFDYRSKGFDDNRGLRIDLLLASQPLAECCVETGIDYEIRSMEKPSDHAPVWATFRR
[0361] SEQ ID NO: 3 - RecJ enzyme from Thermus thermophilus
[0362] MFRRKEDLDPPLALLPLKGLREAAALLEEALRQGKRIRVHGDYDADGLTGTAILVRGLAALGADVHPFIPHRLEEGYGVLMERVPEHLEASDLFLTVDCGITNHAELRELLENGVEVIVTDHHTPGKTPPPGLVVHPALTPDLKEKPTGAGVAFLLLWALHERLGLPPPLEYADLAAVGTIADVAPLWGWNRALVKEGLARIPASSWVGLRLLAEAVGYTGKAVEVAFRIAPRINAASRLGEAEKALRLLLTDDAAEAQALVGELHRLNARRQTLEEAMLRKLLPQADPEAKAIVLLDPEGHPGVMGIVASRILEATLRPVFLVAQGKGTVRSLAPISAVEALRSAEDLLLRYGGHKEAAGFAMDEALFPAFKARVEAYAARFPDPVREVALLDLLPEPGLLPQVFRELALLEPYGEGNPEPLFL
[0363] SEQ ID NO:4 - Bacteriophage lambda exonuclease
[0364] MTPDIILQRTGIDVRAVEQGDDAWHKLRLGVITASEVHNVIAKPRSGKKWPDMKMSYFHTLLAEVCTGVAPEVNAKALAWGKQYENDARTLFEFTSGVNVTESPIIYRDESMRTACSPDGLCSDGNGLELKCPFTSRDFMKFRLGGFEAIKSAYMAQVQYSMWVTRKNAWYFANYDPRMKREGLHYVVIERDEKYMASFDEIVPEFIEKMDEALAEIGFVFGEQWR
[0365] SEQ ID NO:5 - Phi29 DNA polymerase
[0366] MKHMPRKMYSCAFETTTKVEDCRVWAYGYMNIEDHSEYKIGNSLDEFMAWVLKVQADLYFHNLKFDGAFIINWLERNGFKWSADGLPNTYNTIISRMGQWYMIDICLGYKGKRKIHTVIYDSLKKLPFPVKKIAKDFKLTVLKGDIDYHKERPVGYKITPEEYAYIKNDIQIIAEALLIQFKQGLDRMTAGSDSLKGFKDIITTKKFKKVFPTLSLGLDKEVRYAYRGGFTWLNDRFKEKEIGEGMVFDVNSLYPAQMYSRLLPYGEPIVFEGKYVWDEDYPLHIQHIRCEFELKEGYIPTIQIKRSRFYKGNEYLKSSGGEIADLWLSNVDLELMKEHYDLYNVEYISGLKFKATTGLFKDFIDKWTYIKTTSEGAIKQLAKLMLNSLYGKFASNPDVTGKVPYLKENGALGFRLGEEETKDPVYTPMGVFITAWARYTTITAAQACYDRIIYCDTDSIHLTGTEIPDVIKDIVDPKKLGYWAHESTFKRAKYLRQKTYIQDIYMKEVDGKLVEGSPDDYTDIKFSVKCAGMTDKIKKEVTFENFKVGFSRKMKPKPVQVPGGVVLVDDTFTIKSGGSAWSHPQFEKGGGSGGGSGGSAWSHPQFEK
[0367] SEQ ID NO:6-Trwc Cba helicase
[0368] MLSVANVRSPSAAASYFASDNYYASADADRSGQWIGDGAKRLGLEGKVEARAFDALLRGELPDGSSVGNPGQAHRPGTDLTFSVPKSWSLLALVGKDERIIAAYREAVVEALHWAEKNAAETRVVEKGMVVTQATGNLAIGLFQHDTNRNQEPNLHFHAVIANVTQGKDGWRTLKNDRLWQLNTTLNSIAMARFRVAVEKLGYEPGPVLKHGNFEARGISREQVMAFSTRRKEVLEARRGPGGLDAGRIAALDTRASKEGIEDRATLSKQWSEAAQSIGLDLKPLVDRARTKALGQGMEATRIGSLVERGRAWLSRFAAHVRGDPADPLVPPSVLKQDRQTIAAAQAVASAVRHLSQREAAFERTALYKAALDFGLPTTIADVEKRTRALVRSGDLIAGKGEHKGWLASRDAVVTEQRILSEVAAGKGDSSPAITPQKAAASVQAAALTGQGFRLNEGQLAAARLILISKDRTIAVQGIAGKS SVLKPVAEVLRDEGHPVIGLAIQNTLVQMLERDTGIGSQTLARFLGGWNKLLDDPGNVALRAEAQASLKDHVLVLDEASMVSNEDKEKLVRLANLAGVHRLVLIGDRKQLGAVDAGKPFALLQRAGIARAEMATNLRARDPVVREAQAAAQAGDVRKARLHLKSHTVEARGDGAQVAAETWLALDKETRARTSIYASGRAIRSAVNAAVQQGLLASREIGPAKMKLEVLDRVNTTREELRHLPAYRAGRVLEVSRKQQALGLFIGEYRVIGQDRKGKLVEVEDKRGKRFRFDPARIRAGKGDDNLTLLEPRKLEIHEGDRIRWTRNDHRRGLFNADQARVVEIANGKVTFETSKGDLVELKKDDPMLKRIDLAYALNVHMAQGLTSDRGIAVMDSRERNLSNQKTFLVTVTRLRDHLTLVVDSADKLGAAVARNKGEKASAIEVTGSVKPTATKGSGVDQPKSVEANKAEKELTRSKSKTLDFGI
[0369] SEQ ID NO:7-Hel308 Mbu helicase
[0370] MMIRELDIPRDIIGFYEDSGIKELYPPQAEAIEMGLLEKKNLLAAIPTASGKTLLAELAMIKAIREGGKALYIVPLRALASEKFERFKELAPFGIKVGISTGDLDSRADWLGVNDIIVATSEKTDSLLRNGTSWMDEITTVVVDEIHLLDSKNRGPTLEVTITKLMRLNPDVQVVALSATVGNAREMADWLGAALVLSEWRPTDLHEGVLFGDAINFPGSQKKIDRLEKDDAVNLVLDTIKAEGQCLVFESSRRNCAGFAKTASSKVAKILDNDIMIKLAGIAEEVESTGETDTAIVLANCIRKGVAFHHAGLNSNHRKLVENGFRQNLIKVISSTPTLAAGLNLPARRVIIRSYRRFDSNFGMQPIPVLEYKQMAGRAGRPHLDPYGESVLLAKTYDEFAQLMENYVEADAEDIWSKLGTENALRTHVLSTIVNGFASTRQELFDFFGATFFAYQQDKWMLEEVINDCLEFLIDKAMVSETEDIEDASKLFLRGTRLGSLVSMLYIDPLSGSKIVDGFKDIGKSTGGNMGSLEDDKGDDITVTDMTLLHLVCSTPDMRQLYLRNTDYTIVNEYIVAHSDEFHEIPDKLKETDYEWFMGEVKTAMLLEEWVTEVSAEDITRHFNVGEGDIHALADTSEWLMHAAAKLAELLGVEYSSHAYSLEKRIRYGSGLDLMELVGIRGVGRVRARKLYNAGFVSVAKLKGADISVLSKLVGPKVAYNILSGIGVRVNDKHFNSAPISSNTLDTLLDKNQKTFNDFQ
[0371] SEQ ID NO:8-Dda helicase
[0372] MTFDDLTEGQKNAFNIVMKAIKEKKHHVTINGPAGTGKTTLTKFIIEALISTGETGIILAAPTHAAKKILSKLSGKEASTIHSILKINPVTYEENVLFEQKEVPDLAKCRVLICDEVSMYDRKLFKILLSTIPPWCTIIGIGDNKQIRPVDPGENTAYISPFFTHKDFYQCELTEVKRSNAPIIDVATDVRNGKWIYDKVVDGHGVRGFTGDTALRDFMVNYFSIVKSLDDLFENRVMAFTNKSVDKLNSIIRKKIFETDKDFIVGEIIVMQEPLFKTYKIDGKPVSEIIFNNGQLVRIIEAEYTSTFVKARGVPGEYLIRHWDLTVETYGDDEYYREKIKIISSDEELYKFNLFLGKTAETYKNWNKGGKAPWSDFWDAKSQFSKVKALPASTFHKAQGMSVDRAFIYTPCIHYADVELAQQLLYVGVTRGRYDVFYV
Claims
1. A method for detecting an analyte in a medium, said medium containing a light-scattering component, wherein, The light scattering component has a refractive index different from that of the medium; the method includes: - Make the medium come into contact with the nanopores; - Generates the flux of the light-scattering component through the nanopore; - Contact the analyte with the nanopore, such that the analyte affects the flux of the light-scattering component through the nanopore; - Irradiate the medium near the nanopore with one or more light sources; and - As the analyte moves relative to the nanopore, the light scattered by the light-scattering component near the nanopore is measured once or multiple times, thereby detecting the analyte as it moves relative to the nanopore.
2. The method of claim 1, wherein measuring the light scattered by the light scattering component once or multiple times comprises generating a scattering signal corresponding to the flux of the light scattering component through the nanopore.
3. The method of claim 2, wherein measuring the light scattered by the light scattering component once or multiple times includes detecting interference between the scattering signal and the reference beam.
4. The method according to claim 3, wherein the interference is detected by a reflection interferometric contrast microscope, a digital holographic interferometer, an interferometric scattering microscope (iSCAT), or a coherent bright-field interferometer (COBRI).
5. The method of claim 3, wherein the reference beam is reflected from the interface.
6. The method of claim 1, wherein the flux of the light scattering component is from a first volume of medium to a second volume of medium, and wherein one or more measurements of the light scattered by the light scattering component are one or more measurements of the second volume of medium near the nanopore.
7. The method of claim 1, wherein the one or more light sources comprise a laser, a superluminescent diode, and / or an incoherent source.
8. The method of claim 7, wherein the one or more light sources are LEDs.
9. The method of claim 7, wherein the one or more light sources are lamps.
10. The method of claim 3, wherein the scattering signal, the reference beam, and / or the interference therebetween are detected using a detector selected from CCD, CMOS camera, and point detector.
11. The method of claim 10, wherein the point detector is a photodiode.
12. The method according to claim 1, wherein the refractive index of the light scattering component is greater than the refractive index of the medium.
13. The method of claim 1, wherein the light scattering component comprises a hydrophilic, water-soluble molecule.
14. The method of claim 1, wherein the light scattering component is uncharged.
15. The method of claim 1, wherein the light-scattering component comprises sugar or polyethylene glycol.
16. The method of claim 1, wherein the light scattering component does not include fluorophores.
17. The method of claim 1, wherein the flux of the light scattering component through the nanopore is driven by a physical or chemical potential.
18. The method of claim 1, wherein the flux of the light scattering component through the nanopore is driven by a potential or chemical concentration gradient across the nanopore.
19. The method of claim 1, wherein the analyte is a biopolymer.
20. The method of claim 1, wherein the analyte is a polynucleotide or a polypeptide.
21. The method of claim 1, wherein the analyte is not labeled.
22. The method of claim 1, wherein the analyte is not marked with optical markers.
23. The method of claim 22, wherein the optical marker is a fluorophore or a chromophore.
24. The method of claim 1, wherein the movement of the analyte relative to the nanopore is driven by a physical or chemical potential.
25. The method of claim 1, further comprising contacting the analyte with a dynein, wherein the dynein controls the movement of the analyte relative to the nanopore.
26. The method of claim 25, wherein the dynamin is a helicase, polymerase, exonuclease, topoisomerase, folding enzyme, or a variant thereof.
27. The method of claim 1, wherein the medium comprises an aqueous or non-aqueous solvent.
28. The method according to claim 1, wherein the nanopore is a transmembrane nanopore.
29. The method according to claim 1, wherein the nanopore is a protein nanopore, a solid nanopore, a nucleic acid nanopore, or a polymer nanopore.
30. The method of claim 1, wherein the nanopore is a β-barrel protein nanopore.
31. The method of claim 1, wherein the nanopores are present in the membrane.
32. The method of claim 1, wherein the nanopores exist in the droplet interface bilayer.
33. The method of claim 1, wherein the nanopores are present in an array of a plurality of nanopores.
34. A method for characterizing an analyte, comprising performing the method according to any one of claims 1 to 33; and performing one or more measurements as the analyte moves relative to the nanopore, wherein the one or more measurements indicate one or more properties of the analyte, and thereby characterizing the analyte as it moves relative to the nanopore.
35. A system comprising: - A medium containing a light-scattering component, wherein the light-scattering component has a refractive index different from that of the medium; - Nanopores in contact with the medium; - The medium near the nanopore is illuminated by one or more light sources; and - Reference light source.
36. The system of claim 35, wherein the light scattering component is non-fluorescent.
37. The system according to claim 35 or 36, wherein: i) The medium includes an analyte for detection; and / or ii) The system also includes a kinetic protein for controlling the movement of the analyte relative to the nanopore.
38. An apparatus for detecting an analyte, comprising: - A chamber having a volume containing a medium comprising a light-scattering component, wherein the light-scattering component has a refractive index different from that of the medium; - A membrane containing nanopores, wherein the nanopores are in contact with the medium; - One or more light sources for illuminating the volume near the nanopores; and - A detector used to detect light scattered by the light scattering component.
39. The apparatus of claim 38, wherein the detector is configured to detect interference between a scattering signal corresponding to the flux of the light scattering component through the nanopore and a reference beam.
40. The apparatus of claim 38 or 39, wherein the medium comprises an analyte for detection.
41. The device of claim 38 or 39 further includes a kinetic protein for controlling the movement of the analyte relative to the nanopore.
Citation Information
Patent Citations
phi 29 DNA polymerase
US5576204A
A miniature support for thin films containing single channels or nanopores and methods for using same
WO2000028312A1
Deliver of molecules to a li id bila
WO2006100484A2
Lipid bilayer sensor system
WO2008102120A1
Formation of lipid bilayers
WO2008102121A1
